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Staphylococcus aureus is a significant human pathogen and is the primary cause of skin 
and soft tissue infections. Antimicrobial resistance is an ongoing concern, with increasing 
reports of multi-resistant S. aureus infections which have limited options available for 
treatment. New Zealand has high incidence rates of infections caused by S. aureus, with 
the predominant circulating clone often being resistant to the topical antibiotics fusidic 
acid and mupirocin. Healthcare facilities have relied on chlorhexidine as the main 
antimicrobial agent used to prevent and control infections caused by common pathogens 
including S. aureus. Chlorhexidine resistance in S. aureus has been associated with  
qacA, a gene which encodes for a multi-drug efflux pump.  
The objectives of this study were to (i) determine prevalence of qacA in New Zealand 
S. aureus; (ii) correlate prevalence of qacA gene in New Zealand S. aureus strains with 
clonal lineages, susceptibility profiles, and patient demographics; and (iii) examine the 
genetic context of the qacA gene in circulating S. aureus clones. 
The qacA prevalence in New Zealand S. aureus isolates is 7%. Concerningly, presence 
of the qacA gene is associated with the predominant clonal lineage spa type t127 strain 
found in New Zealand. The predominant New Zealand t127 strain is synonymous with 
fusidic acid resistance and, in 45% of cases, mupirocin resistant. The combination of 
qacA with fusidic acid and mupirocin resistance in S. aureus has the theoretical potential 
of being resistant to the three most common topical treatment options used for skin and 
soft tissue infections.  
We were unable to find a statistically significant difference in phenotypic susceptibility 
to chlorhexidine when testing isolates with and without qacA. Despite being unable to 
find reduced susceptibility in qacA carrying strains, these strains continue to be 
associated with failed decolonisation strategies in case control studies. Further work 
could look at the development of an assay in different milieu to detect phenotypic 
expression of qacA which leads to reduced susceptibility to chlorhexidine.  
The qacA gene was found on a ~28 kb plasmid, co-located with genes that confer 
resistance to penicillins and mupirocin (mupA). The representative plasmid (pNZAK1) 
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closely resembles the ubiquitous pMW2 plasmid. Interestingly, mupA and the qac operon 
are found on a ~7 kb insertion sequence. A nucleotide BLAST search of this sequence 
indicates that this genetic arrangement is specific to the ST1, t127 clonal lineage in New 
Zealand. Although not closely located in the genome, qacA and the fusidic acid resistance 
gene fusC are both associated with the predominant t127 clone. These findings suggest 
that the heavy use of topical antibiotics and amoxicillin consumption in New Zealand 
may have contributed to the marked prevalence of qacA in New Zealand S. aureus.  
Taken together, antimicrobial use, including chlorhexidine, has the theoretical potential 
to select out multi-resistant S. aureus leading to the predominance and success of the 
t127 clone and consequently, to the high rates of infection found in New Zealand. Thus, 
consideration should be given to the widespread use of chlorhexidine and the unintended 
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Chapter 1. Introduction 
 Staphylococcus aureus 
Staphylococcus aureus is a commonly encountered human and animal pathogen which 
is associated with skin and soft tissue infection (SSTI) and invasive disease such as 
pneumonia and blood stream infections. S. aureus is part of the Staphylococcaceae 
family, a family of Gram-positive bacteria, known for their ‘grape-like’ clusters in Gram 
stains (1). The Latin term aureus, used for this species, is attributed to the golden colour 
of the organism. S. aureus are facultatively anaerobic, catalase and coagulase positive, 
and β-haemolytic on Columbia sheep blood agar (1).  
 Spectrum of S. aureus infections 
S. aureus infections can manifest in several forms and are not limited to an organ system. 
S. aureus are known to cause SSTIs such as furuncles or carbuncles, impetigo bullosa, 
pyomositis, and scalded skin syndrome (2). Healthcare-associated infections (HCAI) 
such as surgical wound infections, prosthetic device infections, and pleuropulmonary 
infections like pneumonia are also strongly associated with S. aureus (3) and highlights 
the importance of implementing an effective infection control procedure. S. aureus 
bacteraemia (SAB) is often a consequence of different primary clinical foci (3). Case 
fatality rates for SAB have dropped since the introduction of β-lactam antibiotics for 
treatment from 80% to 15-50%. While this rate still seems elevated, several factors 
prevent this number from being lower. These factors include a changing, aging 
population and patients with existing co-morbidities, as well as difficulties associated 
with the management and treatment of complex S. aureus infections (3). 
 Pathogenesis and virulence 
S. aureus colonisation is common in healthy individuals and nasal carriage is found in 
approximately 30% of all adults (4). However colonisation is not exclusively nasal. 
S. aureus has been found on the skin, perineum, and the pharynx (4). In addition, studies 
have also found carriage of S. aureus within the gastrointestinal tract, vagina, and axillae. 
Carriage rates can be variable as some adults are shown to be transient carriers, with 
different S. aureus strains isolated on different occasions, whereas persistent carriers tend 
to carry one strain (4). As an opportunistic pathogen, colonisation with S. aureus requires 
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only a breach to the host’s defence mechanism, making this event the primary catalyst 
for infection (2,5,6). Therefore, those who are persistent carriers of S. aureus are naturally 
more at risk of developing S. aureus infections with the same colonised strain (4).  
Multiple virulence factors (summarised in Table 1) contribute to the success of S. aureus 
in establishing infection. These factors are involved in the adhesion, invading, and 
binding of S. aureus to host tissue (2,7). Furthermore, S. aureus has factors which evade 
host defences (8); and factors that are involved with dissemination of S. aureus to other 
sites resulting in septicaemia or toxin mediated disease (5).  
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Table 1. Summary of S. aureus virulence factors 
Table taken from Gordon and Lowy 2008 (7)  
Type of virulence factors Selected factors Associated genes Associated clinical syndromes 
Involved in attachment MSCRAMMs  clfA, clfB, fnbB, cna, sdr, bbp Endocarditis, osteomyelitis, septic arthritis, 
and prosthetic-device and catheter 
infections 
Involved in persistence Biofilm accumulation, small-colony variants, 
and intracellular persistence. 
Ica locus, hemB mutation Relapsing infections, cystic fibrosis, and 
syndromes as described above for 
attachment 
Involved in evading/destroying host defences Leukocidins, capsular polysaccharides, 
protein A, CHIPS, Eap, and phenol-soluble 
modulins 
lukS-PV, lukF-PV, hlg, cap5 and 8 gene 
clusters, spa, chp, eap, psm-α gene cluster 
Invasive skin infections and necrotising 
pneumonia (CA-MRSA strains that cause 
these are often associated with capsular 
polysaccharides) 
Involved in tissue invasion/penetration Proteases, lipases, nucleases, hyaluronate 
lyase, phospholipase C, and 
metalloproteases 
V8, hysA, hla, plc, sepA Tissue destruction and metastatic infections 
Involved in toxin-mediated disease and/or 
sepsis 
Enterotoxins, toxic shock syndrome toxin-1, 
exfoliative toxins A and B, α-toxin, 
peptidoglycan, and lipoteichoic acid. 
sea-q (no sef), tstH, eta, etb, hla Food poisoning, toxic shock syndrome, 
scalded skin syndrome, bullous impetigo, 
and sepsis syndrome 
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 Methicillin-resistant S. aureus and associated multi-resistance 
Since the introduction of antibiotics, resistance in microbes can be found to all new 
antibiotics shortly thereafter (9). Penicillin, a β-lactam antibiotic, was introduced in the 
1940s as an antibiotic which could effectively treat staphylococcal infections. However 
resistance emerged within a couple of decades in at least 80% of all community 
associated and hospital acquired staphylococcal isolates. Similarly in the 1960s, the 
introduction of another β-lactam antibiotic, methicillin, as an anti-staphylococcal 
alternative, soon gave rise to methicillin-resistant S. aureus (MRSA) rendering 
methicillin inadequate as a treatment option for all S. aureus infections (9). In addition, 
mechanisms of resistance to other classes of antibiotics including fluoroquinolones, 
aminoglycosides, and macrolides have been extensively described, and glycopeptide 
resistance remains an ominous threat (10). The most recently released β-lactam 
antibiotic, ceftaroline, was marketed as an anti-MRSA antibiotic in the post-vancomycin 
era, however emerging resistance to ceftaroline has already been reported with high 
minimum inhibitory concentrations (MICs) observed at levels which are classed as non-
susceptible (11). 
Bacteria that develop or acquire resistance mechanisms have a selective advantage in the 
presence of antibiotics. These resistance mechanisms include efflux pumps, target site 
modification, and destruction of the antibiotic itself (12). Antibiotic destruction is best 
exemplified in penicillin resistance whereby the β-lactamase hydrolyses the β-lactam 
ring found in penicillin, preventing penicillin from binding to penicillin-binding proteins 
(PBPs). PBPs are enzymes found on the cell membrane of S. aureus and aid the 
transpeptidation reaction which links the peptidoglycan chains together in the cell wall. 
β-lactamase production is encoded by the blaZ gene which is regulated by repressor 
proteins BlaI and BlaR1 (Figure 1). Upregulation of β-lactamase production is through 
interaction of the membrane protein BlaR1 with penicillin. This binding results in 
cleavage of protein BlaR1 resulting in BlaR2 interacting with BlaI. This interaction 
prevents BlaI from binding to the operator region which allows access for RNA 
polymerase to bind to the operator region and begin synthesis of the β-lactamase from 
blaZ. This increased expression of the β-lactamase results in penicillin resistant strains 
of S. aureus (9).   
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In the case of methicillin resistance, the mecA gene encodes for penicillin-binding protein 
2a (PBP2a), in which the target PBP has been modified, preventing β-lactam antibiotics 
from binding to the PBP2a. The change from PBP to PBP2a in MRSA is enough to allow 
survival to high concentrations of β-lactam antibiotics. Classically, methicillin resistance 
in S. aureus were associated with hospital-acquired strains, however, in recent years the 
incidence of community-associated MRSA infection has been increasing (13). The rise 
in incidence of community-associated MRSA infections clearly indicates that 
multi-resistance in S. aureus and MRSA is no longer an exclusively nosocomial issue, 
and that prevention of infection also needs to target the community.  
 
Figure 1. β-lactamase expression and regulation in S. aureus by Lowy et al. 
β-lactamase expression is upregulated when penicillin is bound to BlaR1. This leads to a series of reactions 
resulting in the binding of RNA polymerase to the blaZ gene. β-lactamase protein hydrolyses and 
inactivates the β-lactamase ring in Penicillin (14). 
Efflux mediated resistance mechanisms are recognised mainly for resistance to 
fluoroquinolones, antiseptics, and disinfectants. Efflux mediated resistance can be either 
chromosomally- or plasmid- encoded. Efflux systems can confer resistance specific to a 
single compound, or to several classes of antimicrobial compounds (15). The specificity 
of a single efflux pump to a wide range of substrates often leads to resistance to multiple 
compounds making efflux pumps an advantageous and efficient acquisition for bacteria. 
In most cases, efflux pumps work by migrating the noxious substrates from within the 
cell extracellularly using proton motive force or the sodium membrane gradient to 
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energise the pump (15). Antibiotics like fluoroquinolones, phenicols, and topical 
antibiotics like fusidic acid and mupirocin have all been recognised as substrates of 
chromosomally-encoded efflux systems (15). Disinfectants including chlorhexidine, 
cetrimide, ethidium bromide, and benzyl ammonium chloride are recognised substrates 
of plasmid-encoded efflux systems (9,12,15). 
 New Zealand epidemiology of S. aureus 
The incidence of S. aureus infections in New Zealand was well documented by 
Williamson et al. who looked at longitudinal trends in data collected over a 12 year 
period. Incidences were calculated to observe trends in different demographics including 
gender, ethnicity, socioeconomic status using NZDep (NZ deprivation index) score, and 
geographic regions. The paper found New Zealand incidence rates over the 12 years to 
be 127 per 100,000 population per year (16). A notable increase was found in the 
incidence of SSTI which climbed from 81 cases per 100,000 population to 140 cases per 
100,000 population. SSTI incidence was highest in children less than 5 years of age 
(242 cases/100, 000 population/year) and incidence of sepsis and pneumonia is higher in 
those aged 70 or over (62 and 24 cases/100,000 population/year respectively) (16). 
Incidence rates were higher for Māori and Pacific Peoples as well as those who were 
from areas with a higher NZDep score. This disparity in incidence rates seen between 
Māori and Pacific Peoples compared to other ethnicities was still present when adjusted 
for socioeconomic deprivation (16). 
Surveillance of antibiotic resistance of circulating strains of S. aureus in New Zealand is 
regularly performed by the Antibiotic Reference Laboratory (ARL) at the Institute of 
Environmental Science and Research (ESR). Antibiotic susceptibility information is 
collected annually from multiple centres across the country and published publicly. In 
2013, MRSA made up 10.2% of all clinical S. aureus isolates reported (17). This rate sits 
well below reports of over 50% prevalence in the United States of America (USA) in 
2007 and 21% in a combined Europe prevalence survey in 2008 (18,19). In Australia the 
proportion of S. aureus that are MRSA is 17.9% (20). Despite New Zealand rates being 
lower than USA, Europe and Australia, New Zealand MRSA rates have steadily risen 
from 7.5% in 2003. The 2014 annual MRSA survey published by ESR, reports that the 
national period-prevalence has risen from 12.9 per 100,000 in 2005 to 23.8 per 100,000 
resulting in an 85% increase. In the last four years this number has stabilised, however 
 19 
the proportion of strains included in the annual studies has seen a dominant presence of 
the fusidic acid-resistant strain AK3, a community-associated strain of MRSA (Figure 2) 
(21).  
The emergence of fusidic acid resistant isolates as the predominant circulating strain has 
been described in previous surveillance of both MRSA and MSSA. The trend closely 
resembles the increased prevalence of mupirocin-resistant strains when mupirocin was 
available as an over the counter topical antibiotic (22). Fusidic acid has been available as 
an intravenous, oral, and topical antibiotic since the 1960s in Europe and Australia, and 
in the late 1980s in Canada, yet rates of resistance have remained low in Europe and 
Canada despite usage in the clinical setting (23–25). In New Zealand, the rate of fusidic 
acid resistance has been steadily increasing, and is associated with prescribing habits of 
the topical fusidic acid ointment, which is fully subsidised by the NZ Ministry of Health. 
This goes hand in hand with the decreasing mupirocin resistance trend and corresponds 
to the mupirocin ointment being only partially subsidised and being the more expensive 
option to treat skin and soft tissue infections in the community. The emergence of 
resistance to fusidic acid in NZ strains is predominantly driven by two clones, the MSSA 
spa type t127 CC1 (clonal complex 1) and for MRSA, spa type t002 CC5, both of which 




Figure 2. New Zealand MRSA distribution by year and clonal lineage taken out of Annual survey 
of MRSA, 2014, ESR.  
Emergence of AK3 MRSA (dark blue) was evident from 2006 onwards. In 2011 AK3 MRSA were the 
predominant strain of MRSA in New Zealand. AK3 MRSA are known to be fusidic acid-resistant (27). 
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 S. aureus on a molecular level 
S. aureus and their respective genes and genomes have been widely studied due to the 
clinical impact of the organism on health as a whole. Before molecular methods, typing 
of strains relied on phenotypic characteristics like antibiotic resistance profiles or phage 
typing. Development of new technological advances have provided epidemiologists and 
scientists with a novel approach to grouping S. aureus strains by incorporating a variety 
of typing methods on the molecular level by looking at genes and gene expression. Whole 
genome sequencing has now become an important development in microbiology research 
and surveillance as information generated per isolate can provide more data than what 
can be found through a typical typing system. To date, 80 complete and annotated 
genomes of S. aureus are available in the GenBank database to provide a context or a 
reference for any projects involving next generation sequencing. This information is 
invaluable as it allows for continuous progression in the understanding of emerging 
trends in S. aureus infections. 
 Molecular typing methods  
Typing methods are valuable from an epidemiological perspective as they provide 
information beyond what can be detected phenotypically in a diagnostic laboratory. 
Typing is performed for public health surveillance to investigate any emerging trends in 
population health relating to S. aureus. Typing is also critical for outbreak investigations 
by being able to discriminate between related and unrelated strains to inform a public 
health response if required.  
Pulse-field gel electrophoresis (PFGE), or macrorestriction pattern analysis, was the 
initial method used across reference laboratories to type strains on a molecular level. This 
method replaced bacteriophage typing at the Centre for Disease Control and Prevention 
in the late 90s and was found to have better discriminatory power as most S. aureus were 
typable through this method (28). Restriction enzymes (commonly SmaI – a type 2 
enzyme derived from Serratia marcescens) digest genomic S. aureus DNA in an agarose 
plug by cutting at restriction sites creating large fragments of DNA (29). The large 
fragments are then separated through PFGE and visualised as banded patterns on agarose 
gels. Differences in banding patterns may be the result of inclusion or exclusion of repeat 
sequences, or additional mobile genetic elements.  
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Multi-locus sequence typing (MLST) uses sequence analysis to determine sequence 
types by looking at a group of core genes or loci within the genome. Using a central 
MLST database for S. aureus, (https://pubmlst.org/saureus/) the sequences of the PCR 
products of seven housekeeping genes are able to determine allelic profiles for each loci. 
These seven loci genes are arcC, aroE, glpF, gmk, pta, tpi, and yqiL. The S. aureus MLST 
database converts the combination of these allelic profiles into sequence types (29). As 
the genes targeted in this method are core variants, any mutations or changes in 
nucleotide sequence are minimal and sequence typing results are mostly unaffected by 
mobile genetic elements. This makes MLST a useful tool for tracing the evolution of 
specific lineages (8). BURST (Based Upon Related Sequence Types) analysis can group 
sequence types into clonal complexes showing further relatedness between lineages (8). 
Typing of the spa gene is an alternative sequence-based method used for typing S. aureus 
strains. This method amplifies the polymorphic X region of the staphylococcal protein A 
gene. The polymorphic X region is a series of 24 bp repeats, with well conserved 
sequences on either side of the region (8,30). The spa gene is considered one of the core 
variant genes, and the highly variable polymorphic X region allows for S. aureus to be 
typed into different types depending on the repeat pattern of the 24bp repeats. Each 
variation of the 24bp repeat is given a repeat number and the combination and order of 
these repeats denotes the S. aureus spa type (29). The Ridom Spa Server 
(http://www.spaserver.ridom.de) lists different spa types and repeat patterns and 
associated MLST sequence types and clonal complexes.  
Each of the previously mentioned typing methods have advantages and disadvantages. 
Application of the different typing systems largely depends on the nature of surveillance 
required. PFGE is ideal for outbreak settings as analysis takes into account the whole 
genome and comparisons between strains are highly discriminatory. For example, large 
differences in banding patterns in a small outbreak setting can immediately rule out 
unrelated strains (29). However, PFGE is less useful in large surveillance projects as the 
method lacks clonal lineage information. Thus, MLST and spa typing have been widely 
adopted as typing methods for surveillance of S. aureus. Typing of the spa gene has 
shown good correlation with sequence types and clonal complexes making it an ideal 
alternative to MLST (31). This method is considered more efficient than MLST as spa 
typing requires one PCR and sequencing reaction compared with the seven PCR and 
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sequencing reactions required for MLST. Misclassification is a weakness of spa typing 
as specificity may be compromised because of targeting one loci. Microarray-based 
analysis is another method which essentially works as a multiplex PCR which screens 
for different markers and genes of interest. Microarray-based analysis has also shown to 
give good correlation to clonal complexes (32). 
The most significant change in molecular analysis of microbes is the introduction of 
whole genome sequencing (WGS). WGS of S. aureus isolates has the ability to perform 
all the functions of the above methods with the exception of PFGE. WGS is able to 
provide information on genes carried by the strains, and sequencing results for both 
MLST and spa typing. The same reaction can also define SCCmec complexes and has 
the ability to discriminate between clonal lineages as well as PFGE can, by comparing 
single nucleotide polymorphisms (SNPs) in the core genome of S. aureus strains (29). 
This higher resolution of molecular typing has been utilised by public health laboratories 
for surveillance and outbreak investigations. Data interpretation, technical expertise, and 
turnaround time in WGS is still a limiting factor in the application of this technology in 
diagnostic routine medical microbiology. As prices for this service continue to drop, vital 
data generated can provide thorough understanding of the phenotypic and genotypic 
behaviour of the isolate or isolates of interest. WGS data can also assess for resistance 
genes retrospectively if newfound antibiotics are introduced to the market, by looking for 
previously undiscovered genes (33). Another advantage of WGS, which the other typing 
methods do not provide is analysis of the accessory genome and flexibility of analysis of 
the whole genome. 
 S. aureus genome 
The S. aureus genome is approximately 2.8 Mb in size (6,29,34). The core genome of S. 
aureus makes up approximately 75% of the whole genome and is highly conserved 
throughout the species. The core genome is mostly made of genes which are responsible 
for housekeeping and metabolic functions of the organism. The core genome also 
contains virulence factors specific to S. aureus which make this organism more 
pathogenic than other staphylococcal species (34).  
Within the core genome are a group of genes called core variant (CV) genes. CV genes 
are genes with different variants in their sequence which have evolved over time through 
point mutations or recombinations (34,35). These variants are often used to type clonal 
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lineages of S. aureus as they form part of the core genome but are different enough to 
separate into different groups. S. aureus typing methods, like MLST for example, target 
these core genes to provide an allelic profile which confers a sequence type (34). 
All remaining parts of the genome not belonging to the core genome, are termed the 
accessory genome (34). The accessory genome makes up approximately 25% of the 
entire genome. The accessory genome component of the genome differs from strain to 
strain and is often incorporated into the genome through mobile genetic elements. While 
the core genome is known for the basic metabolic functions of S. aureus, the accessory 
genome is largely associated with antibiotic resistance and virulence factors (34). Mobile 
genetic elements are a large part of what makes up an accessory genome, and because of 
the association of antibiotic resistance with highly pathogenic strains, a lot of research 
has been conducted around the genes that are carried on mobile genetic elements. 
 Mobile genetic elements  
Mobile genetic elements (MGEs) are portions of DNA which make up part of the 
accessory genome. MGEs found in S. aureus include bacteriophages, pathogenicity 
islands, staphylococcal cassette chromosomes, transposons, and plasmids. It is also 
important to note that the transfer of MGEs to lineages are highly specific.  
Horizontal gene transfers and exchange rates of genes are often higher in the same 
lineages than between different lineages (35,36). The restriction modification (RM) 
system Sau1 type 1 is responsible for protecting genetic information from incompatible 
transfers of genes between clonal lineages. Foreign DNA will be recognized and then 
digested to prevent the genes from incorporating into the genome. This system of 
restriction enzyme complexes is encoded by genes hsdR, hsdM, and hsdS. HsdS acts as 
the specificity subunit, and is lineage specific. HsdS modifies and digests DNA at 
different sites in different lineages playing a central role in recognising foreign DNA 
ensuring that horizontal gene transfers are lineage specific (36). Consequently, the RM 
system is important for the promotion and thriving of certain lineages of S. aureus by 
regulating the horiztonal gene transfers of MGEs.  
The following describes the different MGEs found in S. aureus and is summarised in 
Table 2. 
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Bacteriophages and pathogenicity islands 
S. aureus can carry from one to four bacteriophages within their cells (35). Virulence 
factors like Panton-Valentine leukocidin genes and enterotoxin A can be found on 
bacteriophages (35). Bacteriophages within the S. aureus cell can be grouped into five 
families by analysing the homology of the integrase genes (36). Integrase genes 
determine integration of sequences into insertion sites. No more than one of each family 
is found within a single S. aureus cell, possibly due to competition for insertion sites or 
phage immunity (34). S. aureus pathogenicity islands (SaPIs) are essentially 
bacteriophages which lack genes to produce the capsid head or tails essential for gene 
transfer. Therefore SaPIs utilise helper phages to transfer genetic material. SaPIs are 
usually small sequences which can be packed up neatly into miniature phage heads 
(8,34,35). Small sequences also mean that SaPIs transfer at a relatively high rate 
compared to other MGEs. 
Staphylococcal cassette chromosome 
The staphylococcal cassette chromosome (SCC) element is most often associated with 
SCCmec which is known to carry the gene for methicillin resistance, mecA. Although 
considered mobile, they are relatively large for MGEs and do not transfer as readily as 
the others. The SCC inserts into the orfX gene in S. aureus and gets incorporated into the 
S. aureus chromosome (34,35). Several classes of SCCmec have been identified and with 
particular interest in SCCmec IV which is found in most community-associated strains 
of MRSA. SCCmec IV has been shown to spread more rapidly than than classes I – III. 
Later classes of SCCmec seem more mobile, potentially because of a reduction in size 
(36). For example, SCCmec IV and VI are 24.0 kb in size and class V is 27.6 kb. Other 
classes of SCCmec range from 32 kb in class VIII to 53 kb in class II. This difference in 
size observed between the SCCmec classes may support the mobility of some classes 
over others. Other mechanisms of resistance found on SCC are mercury resistance and 




Transposons and plasmids 
Transposons are short sequences of DNA which often get incorporated into 
chromosomes, SCC, or plasmids. Transposons often contain information to confer a 
single resistance mechanism (37). Penicillinase genes and macrolide resistance genes are 
carried on Tn552 and Tn554 respectively. However, larger transposons have been shown 
to code for resistance to aminoglycosides, trimethoprim, and tetracycline (36). Plasmids 
are known for their ability to carry multiple genes for antibiotic resistance, in addition to 
genes which encode resistance to detergents and antiseptics. Most of the resistance genes 
found on plasmids are incorporated from acquired transposons (34). Smaller plasmids 
replicate by rolling circle mechanism, however larger plasmids replicate via the theta 
mechanism (34). Mechanisms of transfer for plasmids are mostly through transduction 
although some plasmids carry tra genes for conjugative transfer (34,36). The rep genes 
which encode for replication proteins can be used to classify plasmids into plasmid 
groups. McCarthy et al. found that plasmid families are lineage associated and this 
supports the argument that selective pressures which select for genes in the plasmids are 
responsible for the success of certain clones (39).  
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Table 2. Properties of S. aureus MGEs 
MGEs Description Size Associated genes Reference 
Bacteriophage  Incorporation into 
genome via 
transduction 
 can be lytic, temperate 
or chronic 





 Similar to phages, but 
do not have genes for 
phage construction  




SCC  Integration into open 
reading frame 
sequence (orfX) region 
 Classification of 
SCCmec is a 
combination of ccr and 
mec complexes 






Plasmids  Plasmids transfer by 
conjugation or 
transduction. 
 rep genes aide in 
replication and tra 
genes aide in 
conjugative transfer 
transfer 
Type I - 1-5kb, 









 Chlorhexidine in healthcare 
Chlorhexidine was first described in 1954 and subsequently adopted as an antiseptic used 
in healthcare as a preventative measure to the rising incidence of nosocomial infections. 
The water-soluble form, chlorhexidine digluconate, is extensively utilised because of its 
residual activity, which produces a long lasting, broad spectrum, bactericidal effect. In 
addition, chlorhexidine digluconate use has had low reports of toxicity or irritation by 
health-workers and patients when applied to the skin (42,43). These properties make this 
antimicrobial useful for universal decolonisation procedures. Huang et al. have found 
that the universal decolonisation approach with chlorhexidine is more effective than 
targeted decolonisation and screening-isolation strategies for the reduction of blood 
stream infections with any pathogen, including MRSA (44).  
 Spectrum of activity and mechanism of action 
Chlorhexidine digluconate is a broad-spectrum agent with the most activity observed 
against Gram-positive bacteria (42,43). Chlorhexidine digluconate also has activity 
against Gram-negative bacteria as well as anaerobes, yeasts, and viruses. Chlorhexidine 
is mycobacteriostatic, however the mechanism for this is unknown (43). Despite being a 
broad-spectrum agent, chlorhexidine is unable to kill spores, as it cannot prevent 
germination of spores, but does however, inhibit the outgrowth of the spore (42). 
Chlorhexidine in ethanolic solutions can be tuberculocidal, and sporocidal when used at 
98-100°C. Chlorhexidine is also known to be less effective in the presence of organic 
matter like serum, blood, or pus. The effectiveness of chlorhexidine can also be affected 
by pH with the optimum range being 5.5 – 7.0 (42,45).  
The mechanism of action of chlorhexidine on bacteria depends largely on the 
concentration of chlorhexidine digluconate. In low concentrations (<10 µg/mL) 
chlorhexidine cations in a chlorhexidine digluconate solution are adsorbed onto the 
surface of the bacterial cell by interacting with negatively charged components of the cell 
surface (42,45). This adsorption weakens the cell membrane structure, leading to leakage 
of cytoplasmic contents (42,45). This change is considered irreversible damage and 
occurs rapidly. However, in high concentrations (>90 µg/mL) coagulation of the 
cytoplasmic contents results in rapid cell death, though without cellular leakage (42,45). 
Therefore, low concentrations of chlorhexidine digluconate are considered to be 
“bacteriostatic” and high concentrations are deemed “bactericidal”. Due to the 
 29 
differences in the mechanism of action, high concentrations of chlorhexidine are widely 
used for antisepsis and disinfection (45).  
 Uses and application in healthcare 
Chlorhexidine is used in many clinical settings for the prevention of infection. Repeated 
use of chlorhexidine has shown to be more effective at reducing skin flora than povidone-
iodine due to the long-lasting effect of the agent (46). Primarily, chlorhexidine is used as 
an antiseptic and disinfectant, often found in surgical scrub solutions or in handwashes. 
Chlorhexidine in antiseptics are often used at a concentration of 4% and in combination 
with alcohol for hand disinfection (46). Skin disinfection with chlorhexidine of patients 
and health-workers have also been incorporated into surgical preparation procedures.  
The use of chlorhexidine is more beneficial for the prevention of HCAI when used for 
maintenance and insertion of indwelling devices than when used for pre-operative 
bathing and surgical site preparation. Preparation of the catheter site pre-insertion has 
been shown to reduce intravenous catheter colonisation in neonates when compared to 
povidone-iodine preparation by 50% (47). Similarly, preparation of the pre-insertion site 
of intravenous catheters was also found to reduce the catheter-related blood stream 
infections (CRBSI) by a rate of 49% (95% CI 0.28 to 0.88) as determined by a meta-
analysis study of 4,143 catheters (48). In response to these observed reductions in CRBSI, 
the Centre for Disease Control and Prevention Guidelines for the Prevention of 
Intravascular Catheter-Related Infections, 2011 have recommended the use of 
chlorhexidine at a concentration greater than 0.5% for skin preparation prior to insertion 
of central venous and peripheral arterial catheters (49). The guidelines also recommend 
an alcoholic chlorhexidine gluconate solution to be applied to the skin prior to peripheral 
venous catheter insertion (49). 
Chlorhexidine’s ability to work rapidly and drastically reduce skin flora for prolonged 
periods have led to the use of chlorhexidine to prevent cross-contamination of pathogens 
between patients in hospital environments. Hand-washing with chlorhexidine can reduce 
skin flora by 86% - 92% (46). This reduction was also observed to be sustained for up to 
6 hours (46). Therefore, chlorhexidine has been adopted for decolonisation strategies, 
particularly for MRSA in inpatients of wards with high colonisation pressure, like those 
in intensive care units (ICUs). Decolonisation procedures using skin antisepsis alone 
cannot eradicate MRSA from the patient. Thus, whole-body washing with chlorhexidine 
 30 
is often combined with intranasal mupirocin. Studies which looked at the efficacy of 
decolonisation for the eradication of S. aureus carriage had a success rate of 69% in 
haemodialysis patients at 12 weeks, and 74% at 3 months in a multi-centre study in 
Toronto, Canada (50). The latter study also used doxycycline and rifampin in their 
decolonisation procedure. Another study from the same paper also found that the use of 
chlorhexidine and mupirocin on ICU inpatients was able to reduce the incidence of S. 
aureus infection by 66% over a four year period (50).  
A secondary advantage of chlorhexidine use in healthcare is the reduction of 
vancomycin-resistant Enterococci (VRE) acquisition in ICU patients and environmental 
VRE contamination (46,51). The broad spectrum of chlorhexidine makes it an 
advantageous addition in the prevention of nosocomial infections, particularly with the 
increase in incidence of multi-resistant organisms in hospitals (46). Chlorhexidine is also 
used in oral health and found in mouthwashes, dental gels, and toothpastes. Use of 
chlorhexidine in oral health has shown to inhibit dental plaque formation due to the 
bacteriostatic and residual activity properties of chlorhexidine (43).  
 Bacterial susceptibility to chlorhexidine 
Resistance to chlorhexidine can be either innate or acquired. Innate resistance to 
chlorhexidine in bacteria is primarily due to the structure of the outer layers of the cell 
wall. Despite being known as a broad spectrum agent, chlorhexidine is not effective 
against all organisms. As previously mentioned, chlorhexidine is known to be not as 
effective against bacterial spores or mycobacteria when compared to other Gram-positive 
bacteria (42). Spores are surrounded by a cortex which is a barrier that prevents the entry 
of chlorhexidine into the cell.  Mycobacteria possess a waxy cell wall which is highly 
hydrophobic that provides a barrier to protect the cell from chlorhexidine (42).  
Resistance to chlorhexidine can also come in the form of physiological or phenotypic 
changes in the organism, or in groups of organisms (42). Biofilms are prime examples of 
this, with organisms collectively showing increased resistance to chlorhexidine. 
Populations of species within a biofilm grow at different rates due to the change in the 
uptake of nutrients. Slower growing bacteria, in particular, exhibit increased resistance 
to antimicrobial agents and disinfectants like chlorhexidine (52). However in most 
instances, when an organism is removed from the biofilm and grown in vitro, there is no 
notable decrease in susceptibility when compared to the normal levels of susceptibility 
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observed in the wild-type population (52). Mechanisms which lead to increased 
resistance to disinfectants like chlorhexidine have been hypothesised to be due to the 
following reasons: (i) reduced access of the disinfectant to the organism within the 
biofilm possibly due to the physical access or chemical interaction of the disinfectant 
with the biofilm itself, (ii) the modulation of the environment surrounding the organism, 
(iii) the production of enzymes which degrade or neutralise the disinfectant by 
neighbouring bacteria, or (iv) exchange of genetic information between the micro-
organisms leading to enhanced tolerance to the antiseptic or disinfectant (42). Biofilms 
provide a protective environment in which survival is achieved despite exposure to high 
levels of disinfectant used for preservation or antisepsis. Serratia marcescens, a Gram-
negative bacillus known to cause ventilator associated pneumonia, has been known to 
survive in 2% chlorhexidine in a thick biofilm within the walls of storage containers (53). 
Acquired bacterial resistance to chlorhexidine is of greater concern than innate resistance 
due to the uptake of resistance mechanisms which promote survival of resistant bacteria 
(42). Acquired resistance mechanisms are often related to the incorporation of resistance 
genes found on plasmids. Mechanisms of acquired resistance to chlorhexidine can be due 
to inactivation, or through efflux. It is important to note that acquired resistance can often 
mean an increased MIC from the norm and can also be interpreted as increased tolerance 
to chlorhexidine. Despite an increase in MIC, an organism can still be considered 
susceptible to levels of chlorhexidine commonly used in clinical applications.  
Plasmid mediated resistance in staphylococci is considered to be of greatest concern due 
to the use of chlorhexidine for decolonisation or eradication of MRSA or S. aureus from 
patients in high-risk wards. The genes which have been recognised to confer reduced 
susceptibility to chlorhexidine are the qacAB family of genes (54). Multi-drug resistance 
determinant qacA is commonly located in the pSK1 family of multi-resistant plasmids 
which also encodes resistance to β-lactams and heavy metals (54). Thus, selection for the 
qacAB resistance genes with chlorhexidine has implications on other resistance genes or 
gene networks that are found within the same plasmid or chromosome respectively. This 
will be discussed in detail further in this chapter. The qacA gene can be found in 
coagulase-negative staphylococci as well as S. aureus and confers resistance to 
diamidines, acridines, ethidium bromide, and quarternary ammonium compounds in 
addition to chlorhexidine salts (42). 
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 The qacA gene and QacA protein 
The qacA gene encodes QacA, an efflux mediated pump. The name derives from 
quarternary ammonium compounds, due to the resistance observed to this group of 
compounds. The significance of this protein is that it has been identified in S. aureus and 
has the ability to confer resistance to several different compounds typically used in 
healthcare settings as antiseptics or disinfectants. 
 The qacA gene and expression 
QacA was first described as a multi-drug efflux pump by Tennent et al. in 1989 (55). The 
qacA gene was found within pSK1; a plasmid which also carries other resistance 
mechanisms to other classes of antibiotics, namely the aminoglycosides; gentamicin, 
tobramycin, and kanamycin as well as resistance to trimethroprim (56). The same 
plasmid also conferred resistance to the disinfectants: acriflavine, ethidium bromide, and 
quartenary ammonium compounds such as cetrimide and diamidines (56). In 1985 
Tennent et al. were able to identify this disinfectant resistant phenotype down to carriage 
of a specific locus within the pSK1 plasmid family (56). 
The Tennent et al. study was related to the emergence of an outbreak strain of 
nosocomial, multi-resistant S. aureus in Australia in the late 1970s. This outbreak strain 
was resistant to methicillin, streptomycin, erythromycin, clindamycin, tetracycline, 
gentamicin, and kanamycin. This strain also had variable resistance to rifampicin and 
fusidic acid. Treatment for these strains relied on vancomycin, a “last resort” option for 
S. aureus infections (57). Up to 50% of the outbreak strain isolates had plasmids from 
the pSK1 plasmid family and was of great concern as this strain was associated with 
increased resistance to the widely used antiseptic/disinfectant formulas at the time (57).  
The study and characterisation of the qacA gene and associated repressor gene qacR is 
well described by Rouch et al. (58). Their paper studied a distinct 2542bp nucleotide 
sequence within the pSK1 plasmid which contained the gene which encoded resistance 
to the disinfectant compounds like ethidium or acriflavine and quarternary ammonium 
type antiseptics (58). Rouch et al. found two open reading frames (ORFs) within this 
sequence belonging to the qacA and qacR genes which encode for the proteins for QacA 
and QacR respectively (58).  
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The Rouch et al. study identified that the first of the two ORFs found within the 
nucleotide sequence belonged to qacA. This sequence was deduced to be qacA as the 
sequence length matched the molecular weight of the previously published papers 
describing the QacA protein (55,56). The start codon for qacA was identified as CUG 
which was found in close proximity to the ORF. The CUG start codon is considered 
atypical and is usually an indicator that an external control step is required to regulate the 
expression of qacA (58).  
The second ORF in the Rouch et al. study was later identified to belong to qacR, the gene 
that encodes for the repressor protein QacR (58,59). QacR represses expression of qacA 
by binding to a palindromic sequence found between qacR and qacA termed IR1 
(inverted repeat 1). QacR’s protein structure has a helix-turn-helix motif found on the N-
terminal of the protein which binds to IR1 resulting in the direct interaction of QacR to 
the operator DNA sequence of the qacA gene. This binding inhibits the transcription of 
qacA (Figure 3) (58–60). IR1’s palindromic sequence consists of two 15bp arms which 
are separated by six bases. These six bases between the sequences play little or no part 
in the binding of the QacR protein (60).  
The qacA gene expression is promoted when the diffusible repressor protein QacR is 
bound to substrates that QacA and QacR have in common (61). It is thought that the 
ligand binding portion of the QacR contains several amino acids that these substrates 
could bind to, conforming in a change of shape to the QacR protein structure. This change 
in structure prevents QacR from binding to IR1 thus inducing the expression of qacA 
(60,61). A second inverted repeat sequence IR2 was also hypothesised to be a secondary 
regulatory protein which indirectly regulates the expression of qacA by regulating the 
expression of qacR (61). 
 34 
 
Figure 3. Regulation of qacA expression by Grkovic et al.  
QacR forms a drug complex with the substrate freeing the start codon for the production of QacA 
(62).  
 QacA protein function and structure 
The QacA protein is part of the major facilitator superfamily (MFS) of transport proteins 
(58,60,61,63–65). MFS transport proteins can exhibit uniport, symport, or antiport 
systems for transporting substrates across the membrane. The coverage of substrates by 
MFS is wide and varied; and is integral to the functioning of all living things. Drug 
resistance, in particular, is an important function of MFS in bacteria (66). DHA proteins 
are drug H+ antiporter proteins meaning that the drug substrate is transported out as H+ 
ions are transported into the cell (60,66). This mode of transport can also be termed 
proton motive force and relies on a pH gradient to assist in the efflux of the substrate 
(61,63,66). QacA is categorised into class DHA2 which are DHA transporters which 
have 14 trans-membrane segments (TMS) (61).  
The QacA protein is 55kDa in size and is constructed from a 514 amino acid sequence. 
MFS proteins like QacA have highly conserved amino acid motifs that are important for 
the structure and function of the protein (60). These highly conserved regions throughout 
the structure aid the functionality of the transport mechanism which controls the flow of 
the substrate either in or out of the cell (65). Regions which are not highly conserved 
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among MFS account for the substrate recognition component of the protein. Due to the 
wide array of substrates that QacA can transport, it is hypothesised that the binding site 
of QacA lacks elements that are specific to each of the individual substrates (60). The 
alternate theory of QacA specificity is that the transporter has a flexible binding site 
which can accommodate for the differences in substrate structure. Another hypothesis is 
that there may be specific areas of the binding site which bind to parts of the substrate 
which all share a similar feature – this being the cationic nature of the compounds (60).  
 QacA substrates 
QacA’s multi-drug specificity is an important characteristic, with the potential to confer 
resistance to several antiseptics and disinfectants. Acquisition of this resistance 
mechanism may contribute to the sustained high incidence rates of S. aureus infections 
despite heavy disinfectant and antiseptic use.  
More than 30 substrates have been found to be recognised by QacA, all of which share 
common structural features (60). The common denominator of these substrates is that all 
are cationic and lipophilic. Mitchell et al. investigated the different properties of 
monovalent and divalent antimicrobial cations that were considered potential substrates 
of QacA and QacB. Both QacA and QacB had been observed to confer an increase in 
MIC to chlorhexidine. However, QacA had shown a greater increase than QacB 
exhibiting MICs of 12 μg/mL and 6 μg/mL respectively from a control value of 1 μg/mL 
(67). No change in MIC was noted for alexidine or chlorguanide, an aliphatic derivative 
and monovalent derivative of chlorhexidine respectively. It was also observed that QacA 
had shown increased MICs for all the diamidine compounds tested, where QacB did not. 
This may be due to the second positively charged cation in the diamidine structure which 
is recognised by the negatively charged amino acid substitution seen in QacA that is not 
found in QacB. This amino acid substitution occurs in amino acid 323 found in the TMS 
10 (Figure 4) (60,63–66). 
The structural and sequence similarity between qacA and qacB and their encoded proteins 
stems from the theory that qacA evolved from qacB, as the latter was found in plasmids 
from circulating strains of S. aureus from the 1950s. The qacA gene differs from qacB 
by 7 nucleotides in the sequence resulting in 7 amino acid substitutions. However the 
resulting protein encoded by qacA differs phenotypically from qacB solely because of 
the amino acid substitution found on amino acid 323 (63). This small but significant 
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change from the neutral amino acid alanine in QacB to negatively charged aspartate in 
QacA provides a secondary and strong binding site at amino acid 323 for divalent 
aromatic cations (60,63). This substitution expands the range of substrates which can be 
transported by the efflux protein. Other negatively charged binding sites have been 
shown to be in TMS 1, amino acid 34 and the negatively charged arginine in amino acid 
114 in TMS 4, although the latter occurs in a highly conserved region seen in the DHA 
proteins (Figure 4). Although there are three negatively charged sites in the protein, 
studies have shown that trivalent cations are not recognised substrates of QacA (63). 
 
Figure 4. Trans-membrane diagram of QacA from Paulsen et al. showing α helical structure of 
TMS 10 
Proteins in black are residue differences between QacA and QacB. The proline residues (black P) in TMS 
10 may be involved in the flexibility or conformational changes in the structure to accommodate for a 




 Prevalence of qacA gene and chlorhexidine resistance studies 
Given that chlorhexidine, a widely used antiseptic in healthcare, is a substrate of qacA, 
several studies have focused on the prevalence of qacA carriage and phenotypic 
characteristics of qacA carrying strains. In the era of HCAI with increasingly resistant 
strains of S. aureus, chlorhexidine has become an important compound for the prevention 
of infection in the clinical setting.  
 Prevalence of qacA  
Prevalence of the qacA gene in S. aureus studies have been conducted worldwide with 
variable carriage rate results. Difficulties in comparing the rates of qacA carriage is due 
to study design and inclusion criteria of the study population of S. aureus. Screening for 
qacA gene inevitably led to the screening for the qacB gene as well because of the 
similarities in the gene sequence and primer selection for polymerase chain reaction 
methods (PCR). Therefore a majority of studies stylised the two genes as qacA/B to 
describe their gene of interest. Some methods were able to separate the two genes by 
using probes which bind to a short sequence containing one of the seven nucleotide 
differences between qacA and qacB in a real-time PCR reaction (69). Alternatively, 
sequencing of qacA/B PCR products also enabled studies to detect whether the gene 
amplified was qacA or qacB (64,69–73). The findings of the study are summarised in 
Table 3 below. 
There are more prevalence of qacA in MRSA studies than MSSA due to the increasing 
concern about HCAIs, infection control, and decolonisation of at-risk patients. A number 
of studies looked for mupirocin resistance genes alongside qacA/B as mupirocin, a topical 
antibiotic, and CHX are used together for decolonisation (74–77). Within the studies, 
MRSA qacA/B carriage has been reported from as low as none detected to as high as 
94.7% in an Australian study (78). Prevalence was lower in MSSA isolates with the 
highest prevalence rate reported in Japan at 7.5% (71). Higher rates reported for MRSA 
are likely to be due to more studies involving MRSA, or study designs which included 
highly resistant MRSA strains. Selection pressures from antibiotic use or antiseptic and 
disinfectant use, could still be the driving force behind a higher prevalence of qacA/B in 
MRSA, given that MRSA are historically a healthcare associated issue.  
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Table 3. Summary of qacA prevalence studies 
Location of study Single/multi centre Year of isolate collection Total SA 
qacA/B prevalence (%) 
Clinical / non-clinical Hospital / community1 Reference 
MRSA MSSA Combined  
Japan Single 1993-2001 522 32.6 7.5 23.6 Clinical H (71) 
Glasgow, Scotland2 Multi Not specified 88 15.8 0 11.4 Clinical HC (70) 
Turkey Single Not specified 100 0 4 2 Clinical Not specified  
Taiwan Single 2008-2009 156 43.8 3.3 28 Clinical HC (79) 
Shanghai, China Single 2005-2010 610 4.2 4.8 4.4 Clinical H (80) 
Shanghai, China Single 2011 608 15.7 3.6 11.8 Clinical H (81) 
Malaysia Single 2011 259 70.5 1.8 27 Clinical and carriage H (82) 
Spain Single 1997-2006 111 -3 2.7 2.7 Carriage C (83) 
China Multi 2008-2012 499 7.8 0.6 5.2 Clinical and environmental H (84) 
                                                          
1 Abbreviations H,hospital isolates were used in the study; C, community isolates were used in the study; HC, hospital and community isolates were used in the study 
2 Isolates included Vancomycin-resistant strains from Japan 
3 Denotes that no strains tested or unspecified for this category 
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Location of study Single/multi centre Year of isolate collection Total SA 
qacA/B prevalence (%) 
Clinical / non-clinical Hospital / community1 Reference 
MRSA MSSA Combined  
New Zealand  Multi 2014 751 4.4 7.3 7.1 Clinical HC This study 
USA Single 2004-2009 281 18.5 - 18.5 Clinical paediatric H (85) 
Predominantly USA4 Multi 2011 1962 0.9 - 0.9 Clinical H (86) 
Korea Multi 2006-2009 446 - - 9 Clinical H (76) 
California, USA Multi 2008-2011 829 0.6 - 0.6 Carriage LTCF5 (74) 
Malaysia Single 2009 60 83.3 - 83.3 Clinical and carriage H (87) 
USA and Germany Multi 2009 689 - - 0.7 Clinical and environmental H (88) 
Australia6 Single 2000-2009 151 65 - 94.7 - 65-94.7 Clinical H (78) 
Toronto, Canada Multi 2005-2009 334 2 - 2 Clinical and carriage H (72) 
                                                          
4 Isolates included strains from Iraq, Afghanistan, Europe, and the Caribbean 
5 Long term care facility 
6 Prevalence was recorded as individual results for each year of the study 
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Location of study Single/multi centre Year of isolate collection Total SA 
qacA/B prevalence (%) 
Clinical / non-clinical Hospital / community1 Reference 
MRSA MSSA Combined  
Belgrade, Serbia Single 2007-2009 100 32 2 17 Clinical H7 (89) 
Edinburgh, Scotland Multi 2006 120 8 - 8 Clinical H (90) 
Brazil Multi 2002-2003 74 80 - 80 Unspecified H (91) 
Tokyo, Japan Single 2003 65 52 - 52 Unspecified H (92) 
                                                          
7 Includes hospice facility 
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Interestingly, the prevalence studies in MRSA strains conducted in USA and Canada 
showed low carriage rates of qacA/B, reporting prevalence of less than 2% (72–74). The 
only exception to this is a study conducted by Johnson et al. where prevalence is reported 
at 19% (85). However, this was the only study which used clinical isolates from 
paediatric patients (85). The low prevalence rates compared to the rest of the world may 
indicate that clonal lineage or circulating strains may play a part in the carriage and spread 
of qacA/B genes and is not necessarily due to selection pressure.  
Most studies were not able to provide a current status quo of the prevalence of qacA/B 
carrying S. aureus, often using isolates collected over several years. Only one study 
showed the carriage rate in an unbiased sampling of all S. aureus clinical isolates from a 
hospital in Shanghai, which found carriage rates to be 11.8% (81). Despite the many 
studies on prevalence, little is known about the prevalence of qacA/B in the community.  
 Associated clonal lineages with qacA/B 
Carriage studies of qacA/B have looked for the presence of other co-resistance genes with 
particular interest in mupirocin-resistant isolates of MRSA. This is due to 
decontamination procedures which utilises the two topical agents for the eradication and 
decontamination of S. aureus colonised individuals pre-operatively (75,77). McDanel et 
al. were unable to find co-resistance between high level mupirocin resistance and qacA/B 
carriage amongst MRSA isolates from colonised nursing home residents in California, 
USA (74). McGann et al. described a multi-plex PCR which detects mupA and qacA/B 
genes in MRSA, however the study did not indicate whether any co-detection of mupA 
and qacA/B was found in any of the isolates tested (86). The development of screening 
tests and increased monitoring of co-resistance are important to track emerging trends to 
these topical agents. These two studies did not include molecular typing and therefore no 
correlation was made between gene carriage and clonal lineages. Furthermore, these 
studies also had low numbers of positive isolates, thus molecular typing on these isolates 
would not have indicated a statistically significant correlation of qacA/B carriage with 
any clonal lineages. 
Other studies which included molecular typing showed that qacA/B carriage was seen 
more frequently in ST239 S. aureus which is part of clonal complex 8 (CC8) (76,80,81). 
In Sydney, Australia, Ho et al found that 94.5% of qacA/B containing strains of MRSA 
were ST239 (78). Other published reports from China, Korea, and Taiwan also found 
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that a high proportion of qacA/B containing strains belonged to ST239 and ST5 (CC5), 
namely spa types t037 and t002 respectively (76,80,81).  
ST239 MRSA in New Zealand is commonly known to medical microbiology laboratories 
as Akh4, and is a multi-resistant, hospital-acquired MRSA (27). These strains are 
typically resistant to ciprofloxacin, clindamycin, co-trimoxazole, erythromycin, 
gentamicin, and tetracycline. The predominance of fusidic acid-resistant strains of AK3 
MRSA (ST5) in recent years have driven down the numbers of other MRSA, thus ST239 
Akh4 make up a very small percentage of MRSA in New Zealand.  
 Chlorhexidine MIC and MBC  
Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations 
(MBCs) to CHX were carried out alongside most of the qacA/B prevalence studies to 
detect for phenotypic expression. Phenotypic differences are critical for determining 
whether CHX use can drive the selection for resistant genotypes. For the purposes of this 
section, I will refer to all antibiotics, agents of interest, antiseptics, or disinfectants as 
antimicrobial(s). 
MIC refers to the concentration of the antimicrobial at which growth is no longer visible. 
MBC refers to the concentration at which 99.9% of the colony forming units are killed 
off after sustained exposure, normally by removing the organism from the antimicrobial 
and growing any remaining viable colonies in media absent of the antimicrobial (93). 
Currently, there is a lack of standardisation around methods for testing MIC and MBC to 
biocides in common pathogens. A report entitled “Antibiotic Resistance Effects of 
Biocides” prepared by the Scientific Committee on Emerging and Newly Identified 
Health Risks brought attention to the need for a standardised method to assess biocide 
resistance trends. Although prepared for the European Commission, the problem areas 
identified in the report are of global significance (94). In response to this report Morrisey 
et al. set out to identify epidemiological cut off values (ECOFFs) for several biocides 
including CHX (95). ECOFFs provide an indication of the MIC or MBC to the 
antimicrobial of which 99.9% of wild type strains (strains lacking the gene conferring 
resistance to the agent) sit below. Therefore, if a given organism was found to have an 
MIC or MBC above the ECOFF, it should be considered to have an abnormally high 
resistance to the antimicrobial, and to contain gene(s) conferring resistance to the 
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antimicrobial, and outside of what would be considered to be the “natural” level of 
resistance. 
Assigning ECOFFs for organisms and antimicrobials, or deciding on a value at which an 
organism is considered resistant or non-susceptible, requires methodologies to be 
standardised in order for values to be comparable. Several methodologies have been 
utilised for S. aureus and CHX. The popular choice for MIC methodology is described 
in the Clinical Laboratory Standards Institute document CLSI M26-A (96). MBC 
methodologies were extremely variable although the most popular choice was as outlined 
by CLSI M26-A. Alternative methods varied from including a time-kill study with S. 
aureus strains exposed to CHX at set time intervals (97), or variations from the CLSI 
methodology (70,72,86). Unfortunately CLSI methodology is designed for antimicrobial 
use in clinical applications therefore the method may be a questionable way of 
determining MICs and MBCs for antiseptics or disinfectants (95).  
Due to the variation in methods, reporting of MIC and MBC results were difficult to 
summarise. Different methods yielded very different results, and as there are no 
interpretive standards denoting a resistant or non-susceptible concentration, reporting of 
the results proved problematic to collate. The findings are briefly summarised in Table 
4.  
MIC/MBC findings have been mixed with no clear association established between 
qacA/B carrying S. aureus strains and those which do not carry the gene. This could be 
put down to methodology or the expression of qacA/B in different milieu. Some are of 
the opinion that the MBC reported are several thousand fold lower than what would be 
used in the hospital and any increased MBCs in qacA/B is negligible (98,99).  
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Table 4. Summary of MIC and MBC methods and results for S. aureus and chlorhexidine studies 
Method Summary of MIC and MBC result References 
CLSI method for 
MIC and MBC 
 MIC results were grouped between 2 – 4 
mg/L, and rarely reported above 4 mg/L for 
qacA/B carrying isolates. MICs for control 
strains ranged from 1 – 2 mg/L. 




Variation of CLSI 
method for MBC 
 MBCs ranged from 8 – 16 mg/L 
 One study reported concentrations as 
percentages with MBCs of 0.007% for qacA/B 
carrying strains and 0.002% for control 
strains. 
(70,73) 
MBC with time-kill 
and neutralisation 
step 
 “Kill-rate” shown to be between 8 – 64mg/L 
at different exposure times. 
 MRSA strains had MBCs from 2500 mg/L to 
>5000 mg/L at different exposure times, 
MSSA strains ranged from <4.9 mg/L at 
longest time exposure, to >2500 mg/L at the 





 Rationale for this study 
S. aureus disease continues to be of public health importance in New Zealand. S. aureus 
infections and related medical complications place a significant clinical and economic 
burden on the healthcare system. S. aureus are also becoming increasingly difficult to 
treat as antimicrobials are not being developed at the rate at which resistance emerges. 
Collectively, this compounds the current burden posed by S. aureus disease to the health 
sector. New Zealand’s high incidence of S. aureus disease and incidence disparity 
between ethnic groups indicates a need for greater understanding of underlying factors 
that contribute to high rates of disease. 
The prevention of infection has relied on the use of chlorhexidine for antisepsis in 
healthcare. Widespread use of chlorhexidine in the clinical setting has the theoretical 
potential to select out multiply-resistant strains of S. aureus due to the association of 
qacA with other resistance genes co-located on the plasmid. The location of qacA on the 
mobile plasmid can result in widespread dissemination of these co-located genes, 
particularly if carriage is found in the predominant clones of S. aureus in New Zealand.  
Prevalence studies of qacA and concurrent phenotypic susceptibility to chlorhexidine in 
New Zealand S. aureus have yet to be conducted. In conjunction with the 2014 S. aureus 
survey conducted by ARL, ESR, this study sets out to be the first to determine the status 
quo of chlorhexidine susceptibility in New Zealand S. aureus. 
Accordingly, the aims of this study are to investigate the following hypotheses: 
I. That the prevalence of qacA-containing strains of S. aureus would be higher 
in MRSA and multi-resistant healthcare-associated clonal lineages of S. 
aureus.  
II. That qacA-containing strains of S. aureus have reduced susceptibility to the 
antiseptic chlorhexidine compared with non-qacA-containing strains of S. 
aureus, and that exposure to chlorhexidine can select for more resistant 
phenotypes of S. aureus. 
III. That qacA gene in New Zealand strains of S. aureus are co-located on a 
plasmid with multiple antimicrobial resistance genes. 
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Chapter 2. New Zealand S. aureus isolates used in study 
 ESR S. aureus surveillance isolates and data  
The survey descriptions, methods, and data described in this chapter were carried out and 
published by ARL and the Nosocomial Infections Laboratory (NIL), ESR. The isolates 
and data collected from these surveys were used for this study. The work done for this 
study was designed to enhance and support the published surveillance data by using 
phenotypic and molecular epidemiological analysis including the use of whole genome 
sequencing to investigate chlorhexidine resistance in New Zealand S. aureus isolates. 
Chapter three describes the work that was carried out for this study. 
 New Zealand S. aureus 2014 survey 
The 2014 New Zealand S. aureus surveillance report titled “Demographics, antimicrobial 
susceptibility and molecular epidemiology of Staphylococcus aureus in New Zealand, 
2014” was prepared by ARL and NIL, ESR (102). The survey was conducted as a point-
prevalence survey in 2014. The report was prepared for the New Zealand Ministry of 
Health and is publicly accessible online. This report follows the preceding New Zealand 
S. aureus survey which was conducted in 1999 (22). In addition to the data generated 
from the 1999 survey, the 2014 report also included molecular characterisation of clonal 
lineages, as well as molecular screening for Panton-Valentine leukocidin producing 
strains and epidemiological information to determine demographics of New Zealand S. 
aureus isolates. 
 Sampling of S. aureus survey isolates  
Submitting medical diagnostic laboratories were requested to refer all clinical isolates of 
S. aureus to ESR over a 3 day period, from 18-20 March 2014 inclusive. S. aureus which 
were obtained for patient or health-worker screening purposes were not included in this 
survey. For each isolate which was referred, submitting laboratories were also asked to 
provide epidemiological information about the patient. These included national health 
index numbers (NHI), date of birth, hospitalisation status and whether the patient resided 
in long term care facility. Information about the S. aureus isolate was also requested, 
namely the source of infection and penicillin susceptibility of the isolate. 
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Labtests, which services the community of the wider Auckland region were asked to give 
a representative sub-sample (approximately 40) of all their clinical S. aureus as the total 
numbers would lead to over-representation of that region. Duplicate isolates from the 
same patient were not accepted and for laboratories which submitted 30 or more isolates, 
stratified sub-sampling was performed by age group and by volume of isolates by 
referring laboratories. Nelson Hospital Laboratory was exempt from the above exclusion 
criteria as isolates were receipted post sub-sampling. A total of 751 isolates were sub-
sampled from 1185 of S. aureus isolates referred for the survey from 29 submitting 
medical diagnostic laboratories. 
Epidemiological information was gathered using the NHI number and was used to 
determine the District Health Board, ethnicity, recent hospitalisation history, and 
deprivation index score (NZDep2006) of the patients. Access to this information was 
approved by the Northern Regional Ethics Committee (Ethics ref: 14/NTA/109). This 
data was used to determine demographic information about S. aureus disease in New 
Zealand. This epidemiological information was used in our study to determine 
association of qacA carriage with hospitalisation.  
 Phenotypic susceptibility testing of S. aureus 
Phenotypic susceptibility testing of isolates was performed by the ARL, ESR. 
Antimicrobials selected for testing included cefoxitin, ceftaroline, cephalothin, 
ciprofloxacin, clindamycin, co-trimoxazole, doxycycline, erythromycin, fusidic acid, 
gentamicin, mupirocin, rifampicin, and vancomycin. Agar dilution methods, using 
doubling dilutions, were performed according to Clinical and Laboratory Standards 
Institute (CLSI) standards to determine the minimum inhibitory concentrations (MICs) 
(103). MICs were used for interpretation according the CLSI guidelines (104). Fusidic 
acid and mupirocin were not included in CLSI guidelines and interpretation of these two 
antibiotics used European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) criteria (105). 
Inducible clindamycin resistance was tested using CLSI disc diffusion methods and only 
in the instance when erythromycin tested resistant and clindamycin tested susceptible 
through agar dilution methods (104). Inducible clindamycin resistance is observed by the 
flattening of the clindamycin zone between the clindamycin disc and erythromycin disc.  
 48 
Phenotypic susceptibility data obtained for this survey was used to determine any 
correlation between qacA carriage and antimicrobial resistance profiles. 
 Molecular analyses used in survey relevant to this project 
Clonal lineages were determined using spa typing as outlined in the S. aureus survey. 
The polymorphic X region of the spa gene was amplified using PCR and sequenced by 
the Sequencing Laboratory at ESR with the ABI 3130XL Sequencer. Sequences were 
assigned repeat patterns which dictate the spa type using Ridom StaphType software 
version 2.2.1 (Ridom GmbH, Würzburg, Germany). Methods for this protocol were 
performed as previously described by Strommenger et al. (106). The spa typing 
information for the isolates was used in this study for clonal association with qacA. 
Pulsed-field gel electrophoresis (PFGE) was performed on all isolates which were 
uncharacterised via spa typing. PFGE was performed using a previously described 
method using SmaI-digested genomic DNA (28). Analysis of PFGE banding patterns was 
performed using the BioNumerics software version 6.6. Further analysis of predominant 
spa types used multilocus sequence typing (MLST) to determine sequence types by 
targeting loci arc, aroE, glpf, gmk, pta, tpi, and yqiL and according to protocols outlined 
in the S. aureus MLST website. BioNumerics software (http://www.applied-maths.com) 
was used to analyse sequences and sequence types were determined by using the S. 
aureus MLST website interface. 
Screening for the PVL gene was performed using a duplex real-time PCR assay, targeting 
the lukS-PV gene, and the nuc gene (thermostable nuclease gene specific to S. aureus). 
The description of this assay and corresponding quality control measures are published 
in the aforementioned report (102).  
 New Zealand S. aureus 2014 survey data 
As previously mentioned in section 2.2.1 a total of 1185 isolates were submitted as part 
of the New Zealand S. aureus 2014 survey. 751 isolates were sub-sampled from 1185 
and this sub-sample made up the sample for which data was generated for this study. 
S. aureus that were defined as hospital-acquired were isolates from patients that had been 
in a hospital in the three months prior to the time of specimen collection. Those which 
had no history of hospitalisation in the previous 3 months were defined as 
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community-associated S. aureus. Hospitalisation status was recorded for 679 out of the 
751 isolates with 72 isolates submitted without hospitalisation information. One hundred 
and seventy-eight out of 679 (26.2%) isolates were hospital-acquired S. aureus, and the 
remaining 501 (73.8%) isolates were classified as community-associated.  
Sixty-eight out of 751 (9.1%) isolates were methicillin-resistant. Forty-nine out of the 68 
MRSA in the survey had co-resistance to other antibiotics with the predominant antibiotic 
susceptibility pattern amongst MRSA were fusidic acid-resistant (39.7% n=27).  
Amongst methicillin-susceptible strains, 464 out of 683 (67.9%) were susceptible to all 
antibiotics tested in the survey. Fusidic acid resistance also featured heavily among 
MSSA with 143 out of 683 (20.9%) isolates which were fusidic acid-resistant. The most 
common resistance pattern among MSSA was fusidic acid mono-resistance (12.1%), 
followed by resistance to fusidic acid and mupirocin (6.9%).  
Eighty-nine out of 751 (11.9%) S. aureus isolates tested as non-susceptible (interpreted 
as intermediate or resistant) to erythromycin, and 34 (4.5%) isolates were non-susceptible 
to ciprofloxacin. Non-susceptible antibiotic resistance was also observed to doxycycline, 
clindamycin, rifampicin, and gentamicin. All 751 isolates were susceptible to 
cephalothin, co-trimoxazole, and vancomycin. 
The predominant clonal lineage among MRSA was spa type t002, which is also known 
as the AK3 MRSA strain. This strain made up 57% of all MRSA in the survey. Other 
MRSA strains from the 2014 survey included nine (11.7%) EMRSA-15 (spa types t032, 
t852 and t7964), eight (10.2%) WSPP (spa types t019, t975 and t1133), four (5.8%) 
WR/AK1 (spa type t127), and four (5.8%) USA300 (spa type t008 and t024). The 
remaining strains were either the Queensland strain (spa type t3949) or had no designated 
MRSA strain (spa type t7776, t375 and t311).  
As MSSA do not have designated strain names clonal lineage relied only on spa types 
and associated spa clonal complexes. The two most common strains were spa type t127 
(14.7%) and t189 (10.5%). Each of the remaining spa types represented less than 5% of 
the S. aureus 2014 data set.  
 50 
 New Zealand 2015 Annual MRSA Survey  
The Annual MRSA survey report has been prepared by the ARL and NIL, ESR since 
2005 (107). Prior to this, reports on multi-resistant MRSA were prepared annually for 
the Ministry of Health. The move to the annual MRSA survey was to capture underlying 
emerging trends not captured by the reports on multi-resistant MRSA alone. The design 
of the survey was to gain a cross-sectional view of all MRSA isolated in New Zealand in 
a given time period.  
 Sampling of MRSA 
Routinely microbiology diagnostic laboratories in New Zealand were asked to refer all 
MRSA isolated to ARL and NIL in the month of August 2015. Laboratories which were 
unable to submit within the specified dates were asked to submit isolates over 31 
consecutive days in August 2015. MRSA submitted included both clinical samples and 
screening samples.  
Laboratories were also asked to supply epidemiological information which included 
location of the patient; date of birth; and history of, and current hospitalisation status of 
the patient. In addition, information was provided on the site of where the MRSA was 
isolated, infection or colonisation status of the isolate, and whether the isolate was a 
screening specimen or a diagnostic specimen. Isolates and corresponding information 
from this survey were used for this study for qacA prevalence studies in New Zealand 
MRSA. 
 Phenotypic susceptibility testing 
Phenotypic susceptibility testing was performed on isolates when required to confirm 
strain type using antibiotic resistance profiles and to supplement susceptibility 
information from referring laboratories. Susceptibility methods followed the protocol for 
disc diffusion outlined in CLSI and interpreted using the CLSI criteria (103,104). Fusidic 
acid- and mupirocin-resistance was interpreted using EUCAST criteria (108). 
 Molecular analyses used in survey relevant to this project 
Isolates submitted for the 2015 MRSA survey were typed using methods outlined in 
section 2.2.3. All isolates underwent spa typing. For all necessary isolates, MLST for S. 
aureus and PFGE were done for strain typing if untypable using spa typing. The spa 
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typing information obtained from this survey was used for clonal association studies with 
qacA. 
A multi-plex PCR was used for the detection of mecA, mecC, S. aureus control nuc, and 
PVL gene targeting lukS-PV. Confirmation of MRSA was the presence of either mecA or 
mecC, and the nuc gene. Isolates submitted as MRSA which did not have mecA, mecC, 
or nuc were not included in the survey.  
 2015 Annual MRSA survey data 
There were 1222 isolates submitted to ARL for the 2015 Annual New Zealand MRSA 
Survey. These isolates represent all S. aureus isolated from clinical and screening 
specimens collected over a one month period. Only 1218 of these isolates were available 
to determine prevalence of qacA in the MRSA population. 
Strain assignment was performed on all isolates to group into common MRSA strains 
found in New Zealand. One hundred and eight (8.9%) strains had spa types or 
susceptibility patterns which did not match a recognised MRSA strain. The most 
common strain was AK3 (n=631, 52%), followed by WR/AK1 (n=139, 11%), and the 
Queensland clone (n=123, 10%). Sixty-eight strains were associated with USA300 (6%), 
66 strains with WSPP (5%) and 62 strains with E-MRSA-15 (5%). The remaining strains 
made up less than 2% of the strains available for screening. 
The most common spa type for AK3 was t002 (n=535), t127 (n=100) for WR/AK1, and 
t3949 (n=86) for the Queensland clone strain. 
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Chapter 3. Methods and materials 
 Bacterial control strains and primers  
 Bacterial strains  
The primary data set used was the sub-sampled set of 751 S. aureus isolates from 1185 
submitted for the 2014 National S. aureus survey (102). Accession numbers assigned by 
ARL, ESR were used throughout the study as a primary identifier. 
Additionally, 1218 isolates referred to ARL for the 2015 survey were also screened for 
the presence of qacA (107). Similarly, accession numbers assigned by ARL, ESR for 
these isolates were used throughout the study as a primary identifier. 
Additional control strains used for the study are described below in Table 5. Strains were 
acquired from the Antibiotic Reference Laboratory, ESR (ARL;ESR); New Zealand 
Reference Culture Collection Medical Section, ESR (NZRM;ESR); and Japan Collection 
of Microorganisms, RIKEN BioResource Center (JCM). 
 Primers and probes 
Primers and probes for the real-time PCR component of this study were modified from 
the McGann et al. paper (79). Primers and probes targeted qacA and mupA as genes of 
interest, and femA was used as an internal control for each reaction. Primers and probes 
were purchased from BioSearch Technologies (Novato, California, United States). Probe 
modifications were chosen to ensure wavelength was as close to the 5’ modification used 
in the paper. The TYE665 modification for qacA used in the McGann et al. paper was 
changed to Quasar 705 from Quasar 670 as the emission spectra would be more distinct 
and had less overlap with the CAL Fluor Red modification of mupA. The primers shared 
melting points between 46.5°C and 57.5°C. Probes shared melting points between 58.5°C 
and 60.5°C. 
Primers were reconstituted with UltraPureTM H2O (Invitrogen) to make 100 µM stock 
primer solution, of which 10 µM concentrations of forward and reverse primer mix and 
10 µM probe for each target gene were used as working concentrations. 
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Table 5. Control strains used in this study 




ATCC 14990 – Type strain NZRM; ESR 
ARS 99/577 
S. aureus 
Submitted as part of 1999 national S. aureus 




Submitted as part of 1999 national S. aureus 




Submitted as part of 1999 national S. aureus 




Small multi-drug resistance (smr) on a self-








































Probe TCATACATAGACTCTTCAACAGCAGC Quasar 705 BHQ2 
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 Media and Reagents 
 Agar plates 
5% Columbia sheep blood agar and Mueller Hinton CLSI agar plates were purchased 
from Fort Richard (Auckland, New Zealand). 
 Glycerol broth for storage of isolates 
15% Glycerol broths were prepared by dissolving 3 g of BactoTM tryptic soy broth 
dehydrated culture media dissolved in 100 mL of distilled water over gentle heat. 15 mL 
of ProlaboTM bidistilled 99.5% glycerol was added to the tryptic soy broth mixture. The 
pH was adjusted to a consistent 7.0 using 1M NaOH or 1M HCl.  0.8 mL of the broth 
was dispensed into NuncTM Cryotubes. Sterilisation was achieved by autoclaving at 10 
PSI for 10 minutes.  
 Tryptone Soya Agar for transport of isolates 
40 g of dehydrated OxoidTM tryptone soya agar was added to 1 L of distilled water. 
Ingredients were dissolved on a hotplate and cooled to 50-55°C. The pH was adjusted to 
7.1 - 7.5 using 1M NaOH or 1M HCl. Aliquots of 3 mL were dispensed into glass bijoux 
then autoclaved at 15 PSI for 15 minutes. Once sterilised, the bijoux were laid out to 
create a slope and left to set at room temperature.  
 UltraPure™ DNase/RNase-Free Distilled Water 
UltraPureTM DNase/RNase-Free Distilled Water (Invitrogen) was used for all molecular 
work.  
 Lysostaphin  
1 mg/mL working dilution of lysostaphin was prepared by adding 10 mg of lysostaphin 
(Sigma-AldrichTM) to 10 mL of 10 mM Tris-HCl solution.  
 MgCl2 used for PCR 
MgCl2 was prepared for molecular procedures. 50 mM working dilution of MgCl2 was 
prepared using 225 mL 1M MgCl2 (Sigma
TM) in 4275 mL of distilled water. 
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 Master mixes used for PCR 
AmpliTaq Gold® 360 Master Mix 2x (Applied Biosystems, Life Technologies) was used 
for method validation of PCR and real-time PCR set up. TaqMan® Universal Master Mix 
II, with UNG 2x (Applied Biosystems, Life Technologies) was used for real-time PCR.  
 Magnesium and Calcium stock solutions 
Magnesium and calcium stock solutions were prepared for cation adjusted Mueller-
Hinton broths. Calcium stock solution was prepared by adding 3.68 g of CaCl2.2H2O to 
100 mL of distilled water to make up 10 mg/mL of Ca2+. Magnesium stock solution was 
prepared by adding 8.36 MgCl2.6H2O to 100 mL of distilled water to make up 10 mg/mL 
of Mg2+. 
 Cation Adjusted Mueller Hinton Broth (CAMHB) 
21 g of DifcoTM Mueller Hinton dehydrated media was added to 1 L of distilled water. 
The media was mixed thoroughly then boiled whilst stirring. Once cool, pH was adjusted 
to 7.2 using 1M NaOH or 1M HCl then the solution was autoclaved to reach a desired 
end product pH of 7.3 ± 0.1.  
Cation concentration of the broth was obtained by accessing the certificate of analysis at 
http://regdocs.bd.com/regdocs/searchCOA.do using the product and lot number of the 
dehydrated media.  Cation concentration was adjusted to 20 mg/L for Ca2+ and 10 mg/L 
for Mg2+ according to CLSI standards by adding calcium stock solution and magnesium 
stock solution to the broth. CAMHB was then autoclaved at 15 PSI for 15 minutes for 
sterilisation. The CAMHB was dispensed as required. 
 Chlorhexidine digluconate 
20% (w/v) Chlorhexidine digluconate (Sigma-Aldrich) was used to prepare a working 
dilution. To determine the final concentration of the product, a certificate of analysis was 
obtained from http://www.sigmaaldrich.com/catalog/AdvancedSearchPage.do using the 
product and lot number. The working dilution of chlorhexidine digluconate was prepared 
by converting the final percentage into mg/L units. The final concentration of the 
chlorhexidine product used in this project was 20.2%, thus 1.27 mL was added to 98.73 
mL of distilled water to make 100mL of 2560 mg/L of chlorhexidine digluconate. 
Aliquots of 2.5 mL of the working dilution were frozen at -20°C until ready to be used 
for MIC and MBC assay. 
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 General methods  
 Growth conditions 
S. aureus isolates, and other isolates used as controls were streaked onto Columbia sheep 
blood agar plate and incubated at 35°C in 5% CO2 for 18-24 hours. 
 Storage of isolates 
All strains used in this study were suspended in glycerol broths using a sterile cotton 
swab and kept in a -80ᵒC ultra-low freezer. When accessing isolates from storage, aseptic 
technique was used and broths were kept on ice to prevent defrosting to maintain the 
integrity of the frozen isolate. Cotton swabs were used to scrape the top layer of the 
frozen suspension and inoculate the Columbia sheep blood agar. 
 DNA extract storage 
DNA extracts (templates) were kept in a -20°C freezer until ready for use. Extracts were 
defrosted at 4°C before addition to the PCR reaction.  
 Transport of isolates 
S. aureus isolates were inoculated onto Tryptose Soya Agar then incubated overnight at 
37ᵒC. All bijoux were parafilmed and kept at ambient temperature for the duration of the 
transport.  
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 Molecular Methods 
 DNA extraction using boil method 
A rice grain sized of overnight S. aureus culture was suspended in 250 µL of Ultra-
pureTM water in an Eppendorf Safe-lock 1.5 mL tube using a sterile 10 µL loop. Tubes 
were placed in a 100°C heating block for 30 minutes then removed from the heating 
block and left to cool at room temperature. Tubes were spun at 13,000 rpm for 3 minutes 
then stored ready for use.  
 DNA extraction using lysostaphin 
A rice grain sized of overnight S. aureus culture was suspended in 250 µL of Ultra-
pureTM water in an Eppendorf Safe-lock 1.5 mL tube using a sterile 10 µL loop. 3 µL of 
1 mg/mL lysostaphin was added to the suspension and mixed by pipetting up and down 
then placed in a 37°C water bath for 30 minutes. Tubes were transferred to a 100°C 
heating block for 30 minutes then removed from the heating block and left to cool at 
room temperature. Tubes were spun at 13,000 rpm for 3 minutes then stored until ready 
for use. 
 PCR for primer validation  
PCR was performed to validate primer performance for qacA, mupA, and femA. The 
primer concentration and PCR protocol for each reaction was adapted from McGann et 
al. (86). Each reaction was performed as a single 25 μL reaction. 1.5 μL of DNA extract 
was added per reaction.  
Each reaction mixture used the AmpliTaq Gold® 360 Master Mix, 1.25 μL of MgCl2 
solution, primer mix as specified in Table 7, with the remaining volume made up with 
UltraPureTM DNase / RNase-Free Distilled (Invitrogen) water.  
PCR was performed on the ProFlexTM 3 x 32-well PCR system. Protocol was set at 95ᵒC 
for 2 minutes as an activation step, followed by 40 cycles of 95°C for 10 seconds and 
56ᵒC for 45 seconds, with a final extension of 56°C for 2 minutes then hold at 10°C until 
removed from the PCR system.  
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Table 7. Primer mix volume required and final concentration for primer validation PCR 
PCR reaction 




25 μL reaction 
mixture (μM) 
Product size (bp) 
qacA 2.0 0.40 118 
mupA 0.75 0.15 76 
femA 1.0 0.20 116 
 Gel electrophoresis and documentation system 
PCR products were visualised by presence or absence of the gene of interest using gel 
electrophoresis. Gel electrophoresis was performed on the E-Gel® Electrophoresis 
System, using the E-gel EX 2% single comb gels. Invitrogen 100 bp DNA Ladder (Life 
Technologies) was loaded into lane M. The gel was run on the iBaseTM Power System 
for 15 minutes. Gel Doc XR Imager was used for documenting gel visualisation. 
 Reaction mixture preparation for real-time PCR to screen for qacA and 
mupA  
Each reaction was prepared as a 20 μL, duplex reaction. The femA gene target was used 
as an internal control to validate each reaction. 2 μL of DNA extract was required for 
each reaction. The reaction mixture was prepared in bulk for the number of reactions 
required and prepared on ice or in a cold block. 
For qacA, the primer concentration was optimised to have a femA and qacA primer 
concentration of 0.3 μM and a femA and qacA probe concentration of 0.125 μM. 
Universal Master Mix II with UNG was used for each reaction with the addition of 1 µL 
of MgCl2. The remaining volume was made up with UltraPure
TM DNase / RNase-Free 
Distilled (Invitrogen) water.  
Similarly for mupA, the primer concentration for mupA and femA was 0.3 μM and mupA 
and femA had a probe concentration of 0.125 μM and was performed in a duplex reaction 
using the same master mix, MgCl2 and water amounts as for the qacA real-time PCR.  
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 Real-time PCR for qacA and mupA 
Real-time PCR reactions were all performed in Bio-Rad Hard-Shell® PCR 96 well 
plates. Each run had a maximum of 93 test isolates from the survey, plus control strains 
NZRM 2205 S. epidermidis as the negative control, ARS99/580 S. aureus as positive 
control, and DNase / RNase free water as the negative template control. 
DNA extracts were defrosted at 4°C and were spun down at 13,000 rpm for 1 minute. 
2 µL of DNA extract was required for each reaction. 
Real-time PCR was performed on the Bio-Rad CFX 96 TouchTM. Fluorophores selected 
for qacA screening were FAM and quasar 705 for femA and qacA reaction respectively. 
Fluorophores selected for mupA screening were FAM and Cal Red 610 for femA and 
mupA respectively. The protocol used was 50°C for 2 minutes, 95ᵒC for 10 minutes, 
followed by 45 cycles of 95°C for 10 seconds and 55°C for 45 seconds. Plate reading 
was programmed after each cycle.  
A positive reaction for qacA was indicated when the Cq value was less than 38 for qacA 
and femA. A negative result for qacA had a Cq value of greater than 38 for qacA and less 
than 38 for femA. For a valid run, negative controls had values of greater than 38 for both 
qacA and femA, and positive controls had values of less than 38 for both femA and qacA. 
Any sample which had a femA value of greater than 38 may indicate a degradation of the 
fluorophores or insufficient DNA within the extract, and was repeated using the DNA 
template from the lysostaphin extraction.  
Similarly the mupA real-time PCR used the same cut-off values for Cq as that of the qacA 
real-time PCR. A positive reaction for mupA was indicated when the Cq value was less 
than 38 for mupA and femA. A negative result for mupA had a Cq value of greater than 
38 for mupA and less than 38 for femA. For a valid run, negative controls had Cq values 
of greater than 38 for both mupA and femA, and positive controls had Cq values of less 
than 38 for both mupA and femA. 
 61 
 Phenotypic susceptibility to Chlorhexidine 
The method that was used for phenotypic susceptibility testing is as described in the CLSI 
M26-A document ‘Methods for Determining Bactericidal Activity of Antibacterial 
Agents; Approved Guidelines’ (96). The CLSI M26-A document outlines procedures for 
determining minimum inhibitory concentrations (MICs) and minimum bactericidal 
concentrations (MBCs) in a broth microdilution method. This method is not restricted to 
any specific antimicrobial agent, however the primary use of this document in clinical 
microbiology laboratories is for antibacterial agents that are used for the treatment of 
infections at concentrations that are safe for use in humans.  
 Selection of organisms for phenotypic susceptibility testing 
Isolates which screened positive for qacA were all tested for phenotypic susceptibility to 
chlorhexidine. For the control group, strains were matched on spa type. For spa types 
which had no qacA negative equivalent, the next qacA negative isolate was selected.  
 Preparation of suspensions 
CLSI M26-A recommends that the number of organisms within each well in a 96 well 
plate using the broth microdilution method to be 5 x 104 colony forming units (cfu) (96). 
In order to achieve this, the following suspension preparation method was used.  
Using a sterile loop, 3 or 4 colonies of an overnight culture of S. aureus were touched 
then inoculated into 2 mL of CAMHB. This inoculum was incubated at 37°C for 2 hours 
in order for organisms to reach logarithmic phase.  
This inoculum was adjusted to 0.5 McFarland using the Siemens Turbidity Meter by 
addition of CAMHB if required. 150 μL of the 0.5 McFarland suspension was added to 
15 mL of CAMHB. This suspension was considered the final working inoculum used to 
inoculate the 96 well plate.  
 Preparation of 96 well plate with chlorhexidine digluconate for broth 
microdilution  
The broth microdilution method using a 96 well plate was set up to test four specimens 
in duplicate, with concentrations in doubling dilutions as recommended by the CLSI 
M26-A document (96). 
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Working dilutions of chlorhexidine digluconate were prepared and ranged from 0.25 
mg/L to 256 mg/L. The final concentrations in the 96 well plate after the addition of the 
inoculum ranged from 0.12 mg/L to 128 mg/L. Dilutions were prepared in bulk with 
50 μL of each dilution aliquoted into wells in each column as outlined in Table 8. Wells 
in column 12 were used as a growth control with 50 μL of CAMHB aliquoted into these 
wells.  
This dilution method was prepared as suggested by CLSI for broth microdilution. The 
primary source for this dilution method uses 2560 mg/L chlorhexidine digluconate as 
described in section 2.4.10, with each following dilution using dilutions that were 
prepared in a previous step as specified in the table below. CAMHB were used as diluents 
for each step.  
















1 Working dilution 2560 1 9 256 128 1 
2 Step 1 256 2 2 128 64 2 
3 Step 1 256 1 3 64 32 3 
4 Step 1 256 1 7 32 16 4 
5 Step 4 32 2 2 16 8 5 
6 Step 4 32 1 3 8 4 6 
7 Step 4 32 1 7 4 2 7 
8 Step 7 4 2 2 2 1 8 
9 Step 7 4 1 3 1 0.5 9 
10 Step 7 4 1 7 0.5 0.25 10 
11 Step 10 0.5 2 2 0.25 0.12 11 
 Inoculation of the plate 
Each isolate was tested in duplicate, therefore the working inoculum, as prepared in 
section 3.5.2, was added to two rows on a 96 well plate. 50 μL aliquots of the working 
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inoculum was added to to the wells starting from the control, then working from the 
lowest concentration to the highest concentration. The 96 well plate was incubated at 
37°C for 18 – 20 hours.  
 Determining MIC endpoints 
The MIC is the concentration of the antimicrobial agent where no visible growth can be 
seen. Using a mirrored plate reader, the MIC for the isolate is determined to be the 
concentration of the well where no growth can be seen with the naked eye.  
Due to the nature of this assay, MIC results can vary within 1 to 2 dilution steps for any 
antibiotic organism combination. Isolates were done in duplicate to address this issue to 
ensure that the results for MICs were valid. However, because the concentrations were 
in doubling dilutions, the concentration values were not calculated as an average of the 
two results. Instead the first result was taken, with the second value to validate the result 
by being within one dilution of the first.  
MIC values that gave anomalous results, did not have consistent growth patterns within 
the 96 well plate, or were not within one dilution of each other were repeated.  
 Setting up MBC from the 96 well plate 
The MBC is the concentration where 99.9% of colony forming units (cfu) are killed. 
MBC is performed following MIC determination.  
Using the MIC broth microdilution plates, 10 µL of broth was mixed then aliquoted from 
wells with no visible growth and plated and spread onto Mueller Hinton plates for colony 
counts. Each well was done in duplicate. A rejection value of 20 cfu between the 
duplicate samples (the sum of the duplicates has less than 20 cfu) was used to determine 
that the antibiotic level was lethal in the well that the colony count was taken from. This 
rejection value is lower than our intended inoculum within the wells and MBC results 
would potentially be slightly elevated and more sensitive to account for any variability 
in the inoculation process.  
Each MBC for the isolates was performed in duplicate alongside the MIC. Any which 
showed anomalous results or paradoxical effect had the MIC and MBC repeated. The 
first MBC value was taken due to the variable nature of this assay with the second used 
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as validation. The duplicate MBC values had to be within one doubling dilution factor 
from each other. 
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 Statistics for analysis of results 
 Analysis for the prevalence of qacA 
SPSS software was used for analysis for the prevalence of qacA. Categorical variables, 
namely antibiotic resistance profiles, clonal lineages and hospitalisation status used Chi-
square (χ2) analysis to determine associations of these profiles with qacA carriage. A 
p value of less than 0.05 was considered statistically significant. 
 Analysis of phenotypic resistance to chlorhexidine 
SPSS software was used to determine the difference in phenotypic chlorhexidine 
resistance between qacA carrying isolates and the control group. The Mann-Whitney U-
test was used for susceptibility data analysis as MIC and MBC values are non-parametric. 
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 Whole Genome Sequencing (WGS) 
 Isolates selected for WGS 
Five representative isolates were selected for whole genome sequencing in order to 
determine the location of the qacA gene and proximity to other associated resistance 
genes. Isolates were selected from throughout the dataset that proportionally represented 
the different phenotypes and spa types of qacA isolates within the survey. ARS14215 
inclusion was based on mupirocin suceptibility and ARS1456 was chosen on the basis 
that it had a different spa type than the others but had the most common susceptibility 
pattern of being mupirocin- and fusidic acid-resistant.  







Fusidic acid MIC 
(Interpretation) 
ARS1428 2015-09176 t127 R R 
ARS1444 2015-09177 t127 R R 
ARS1456 2015-09178 t128 R R 
ARS1498 2015-09179 t127 R R 
ARS14215 2015-09180 t127 S R 
 Sequencing  
Genomic DNA was extracted from isolates using the DNeasy Blood and Tissue 
Extraction Kit (Qiagen) according to the manufacturer’s instructions. The Nextera XT 
DNA Library Preparation Kit (Illumina) was used to prepare the genome for sequencing 
on the Illumina Next-seq with 2- by 150 bp paired end chemistry. 
 Comparative analysis of S. aureus isolates 
Isolate similarity was assessed using the Nullarbor pipeline 
(https://github.com/tseemann/nullarbor). Raw paired end sequencing data for each 
isolate was used for the input into Nullarbor. The S. aureus MLST scheme was used for 
MLST analysis, MSSA 476 (Table 10) was used as a reference genome. The pipeline 
also included an identification step as well as providing a report on the quality of 
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sequences. Maximum likelihood tree and single nucleotide polymorphism distance 
matrix was taken from the report generated from this pipeline. 
 De novo assembly and annotation of the genome 
Raw sequence data was quality trimmed using Trimmomatic (version 0.35) 
(http://www.usadellab.org/cms/?page=trimmomatic). Parameters were set to exclude 
bases with phred scores of less than 20 and to exclude reads that were less than 100 bp 
in length. 
Raw sequence data was de novo assembled using SPAdes Genome Assembler v3.5.0 
(http://bioinf.spbau.ru/spades). Quality of assemblies was assessed using QUAST 
(http://quast.bioinf.spbau.ru/). Assembled scaffolds were imported into, and annotated 
using the Geneious v8.0.5 software package (http://www.geneious.com/). Imported 
sequences were annotated using the annotation function in Geneious. Annotations were 
primarily from reference S. aureus genomes downloaded from NCBI 
(http://ncbi.nlm.nih.gov) through Geneious. Reference S. aureus genomes were selected 
based on sequence types and susceptibility profiles. Additional genes of interest were 
also downloaded from NCBI through Geneious for annotations that were not found 
within the reference S. aureus genomes, these genes being mupA, qacA and qacB with 
the corresponding regulator gene qacR. Genomes and genes used for annotation are 
summarised in Table 10. 
 Determining genetic context of qacA 
A BLAST (Basic local alignment search tool) search function was used to search for 
qacA-containing contigs using Geneious software (Biomatters). Co-location of the rep 
with qacA on the same contig was used to determine plasmidic location of qacA.  
Contigs were aligned to genes in common to each contig. These genes included rep, blaZ, 
mupA (IleS), qacA, qacR, and qacB. Consensus sequences from each of the alignments 




Table 10. Genes and genomes used for annotation 
Reference genome / gene Sequence type Description / Resistance profile Size (bp) NCBI code 
S. aureus strain MSSA476, complete 
genome 
ST1 Complete genome of common global methicillin-susceptible 
strain  
2,799,802 NC_002953 
S. aureus plasmid pSAS, complete genome - Plasmid belonging to S. aureus strain MSSA 476 genome 20,652 NC_005951 
S. aureus subsp. aureus Mu50 DNA, 
complete genome 
ST5 Complete genome of vancomycin- and methicillin- resistant 
strain 
2,878,529 BA000017 
S. aureus subsp. aureus Mu50 plasmid 
VRSAp DNA, complete sequence 
- Plasmid belonging to S. aureus subsp. aureus Mu50 genome 25,107 AP003367 
qacA gene - Antiseptic resistance gene coding for efflux protein QacA 1545 NC_007931 
qacR / qacB gene - Antiseptic resistance and regulator gene for efflux protein 
QacB and QacR repressor protein 
2421 NG_035045 
mupA gene (ileS2 gene) - Isoleucine tRNA ligase 2 encoding protein which encodes 
resistance to mupirocin 
3553 HQ625435 
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Chapter 4. Results: Prevalence, clonality and co-resistance 
patterns of qacA-containing S. aureus in NZ 
 Introduction 
As previously mentioned qacA prevalence in S. aureus has been widely studied due to 
the association of this gene to chlorhexidine resistance. Several of these studies targeted 
specific S. aureus subgroups or populations and consequently, there are very few studies 
that looks at prevalence on a national level. The prevalence of qacA in New Zealand 
S. aureus isolates has not been previously studied. We set out to determine the prevalence 
of qacA in New Zealand in addition to the 2014 S. aureus survey conducted by ESR 
(102). Additional analysis for this section looks at correlations between clonal lineages, 
isolate acquisition status, and various antibiotic resistance patterns. Several studies have 
simultaneously screened for the presence of qacA and mupA in S. aureus due to the use 
of chlorhexidine and mupirocin for decolonisation procedures. Thus, isolates from the 
2014 S. aureus survey were also screened for mupA.  
As numerous qacA prevalence studies target MRSA isolates due to the association of 
both these elements with hospitalisation and decolonisation, we also screened the 2015 
MRSA survey for qacA to determine prevalence for New Zealand MRSA (107).   
 Results from qacA studies in 2014 S. aureus survey 
 Prevalence of qacA in 2014 S. aureus survey 
Fifty-three out of 751 (7%) isolates carried the qacA gene. A summary of the prevalence 
and various associations is presented in Table 14. 
 Association of qacA with MRSA / MSSA 
Three out of 67 (4.4%) MRSA strains had qacA. Fifty out of 684 (7.3%) MSSA strains 
had qacA (Table 13). This result does not support the hypothesis that prevalence of the 
qacA gene is higher among methicillin resistant strains of S. aureus. This result may not 
be an accurate a representation of the true prevalence of qacA in New Zealand MRSA 
due to the small number of MRSA included in this survey.  
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 Association of qacA with other antimicrobial resistance 
Antimicrobial resistance patterns of qacA positive isolates from the 2014 S. aureus 
survey were evaluated to determine predominant resistance profiles. All qacA positive 
isolates were susceptible to cephalothin, clindamycin, co-trimoxazole, doxycycline, 
gentamicin, and vancomycin.  
Only three out of 53 (6%) qacA positive strains were fully susceptible to all 
antimicrobials tested. Fusidic acid (Fus) resistance was found in 50 out of 53 (94%) qacA 
positive isolates. Mupirocin (Mup) resistance was found in 40 out of 53 (75%) isolates, 
all of which were also fusidic acid-resistant. This represented the most common 
antibiogram of the qacA positive isolates (Table 11).  
Co-resistance of fusidic acid with ciprofloxacin (Cip) and / or erythromycin (Ery) was 
found in 3 out of 53 isolates, all of which were not resistant to mupirocin. None of the 
qacA positive isolates had mono-resistance to mupirocin.  
Table 11. Summary of antimicrobial resistance profiles for qacA positive isolates 
Antimicrobial resistance profile Number (%) 
Resistant to:  
 Fus, Mup 40 (75) 
 Fus 7(13) 
 none 3 (6) 
 Fus, Cip, Ery 2 (4) 
 Fus, Cip 1 (2) 
Total  53 
 
 Association of qacA with isolate acquisition – hospital vs community  
Prevalence of qacA was calculated for each hospitalisation status of the 2014 S. aureus 
survey. Nine out of 178 (5%) hospital acquired isolates tested positive for qacA. 
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Forty-two out of 501 (8%) community-acquired isolates tested positive for qacA. This 
result does not support the hypothesis that prevalence of qacA is higher in hospital-
acquired isolates (Table 12).  
Table 12. S. aureus acquisition and qacA carriage for 2014 S. aureus survey 
Likely place of acquisition 
No. of isolates with qacA 
(Total n=53)  
Proportion of isolates with 
qacA (%) 
Hospital (n=178) 9  5 
Community (n=501) 42  8 
Unknown (n=72) 2  3 
 Association of qacA with clonal lineages 
The prevalence of qacA was highly clonal, such that 41 out of 53 (77%) were spa type 
t127. Three isolates with spa type t127 were WR/AK1 MRSA strains. The remainder of 
isolates were shared among nine other spa types as indicated in Table 13.  
Table 13. Distribution of spa type for qacA carrying S. aureus 
spa type 
No. of isolates with qacA 
(Total n=53) 
Proportion of isolates with 
qacA (%) 
t127 41 77 
t1784 3 6 
t2601 2 4 
Other1 7 13 




Table 14. Summary of 2014 S. aureus isolates and associations with qacA 
Characteristic (n) No. qacA positive (%) No. qacA negative (%) p1 
All S. aureus isolates (751) 53 (7) 698 (93) - 
Hospital vs Community2     
 Hospital-acquired (178) 9 (5) 169 (95) 0.148 
 Community-associated  (501) 42 (8) 459 (92)  
MRSA vs MSSA    
 MRSA (67) 3 (4) 64 (96) 0.388 
 MSSA (684) 50 (7) 634 (93)  
spa type    
 t127 (105) 41 (39) 64 (61) <0.001 
 t189 (71) 0 (0) 71 (100) 0.015 
 t002 (67) 0 (0) 67 (100) 0.018 
 t1265 (28) 0 (0) 28 (100) 0.137 
 t084 (23) 0 (0) 23 (100) 0.179 
 t645 (23) 0 (0) 23 (100) 0.179 
Antimicrobial resistance profiles    
 Mupirocin-resistant3 (43) 32 (74) 11 (26) <0.001 
 Fusidic acid-resistant (127) 39 (31) 88 (69) <0.001 
 Mupirocin- and fusidic acid- 
 resistant (51) 
38 (75) 13 (25) <0.001 
1p value of <0.05 was considered statistically significant. 
2 Hospitalisation criteria determined by hospitalisation three months prior to the date of sample collection. Community isolates 
were from patients who had not been to a hospital three months prior to sample collection. 72 isolates had undefined 
hospitalisation details and were not included for this data. 
3 High level mupirocin resistant (MIC >256 µg/mL) criteria used. 
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 Results from qacA studies in Annual 2015 New Zealand MRSA 
survey 
 Prevalence of qacA 
Ninety out of 1218 (7%) of the 2015 New Zealand MRSA isolates carried the qacA gene. 
This prevalence is similar to the prevalence of qacA in isolates from the 2014 New 
Zealand S. aureus survey.  
 Association of qacA with clonal lineages 
The prevalence of qacA amongst MRSA was also highly clonal. Eighty-one out of 100 
(81%) qacA positive MRSA were spa type t127. The clonal lineages for the remainder 
of qacA positive isolates not represented in Table 15 were made up of non-t127 WR/AK1 
MRSA strain (n=4), EMRSA-15 strain (n=1) and spa types which are not associated with 
any currently recognized MRSA strain (n=2). These results have been summarised in 
Table 15. 
Table 15. Summary 2015 MRSA and association with qacA carriage by spa and strain type 
Characteristic (n) No. qacA positive 
(%) 
 No. qacA negative 
(%) 
p1 
All MRSA isolates (1218)  90 (7) 1128 (93) - 
spa type – MRSA strain type    
 t002 - AK3 (538) 2 (<1) 533 (>99) <0.001 
 t127 - WR/AK1  (100) 81 (81) 19 (19) <0.001 
 t3949 - Queensland clone (86) 0 (0) 86 (100) 0.007 




 Association of mupA with qacA  
 Mupirocin resistance  
Mupirocin susceptibility was tested and recorded for 751 S. aureus isolates from the 2014 
survey. Eighty-three out of 751 (11%) isolates of S. aureus isolates tested had elevated 
mupirocin MICs (> 2 mg/L). Sixty-one out of 83 (73%) of these isolates with elevated 
MICs displayed high level mupirocin resistance. 
 Prevalence of mupA in mupirocin resistant strains 
All 83 strains with elevated mupirocin MICs were screened for mupA gene as described 
in section 3.4.6. Sixty-one out of 83 (73%) mupirocin resistant strains were mupA 
positive and had a direct correlation with isolates that displayed high level mupirocin 
resistance. The mupA gene was not detected in isolates which displayed low level 
mupirocin resistance. 
 Association of qacA with mupA 
All qacA positive isolates that were mupirocin-resistant tested positive for mupA. This 
association is statistically significant and suggests that these genes may be closely linked 
within the S. aureus genome. These results have been summarised in Table 16. 
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Table 16. Summary of mupA and associations with phenotypic mupirocin resistance and qacA 
carriage 
Characteristic (n) No. mupA 
positive (%) 
 No. mupA 
negative (%) 
p1 
Mupirocin resistant isolates (83) 61 (73) 22 (27) - 
Mupirocin resistance    
 High level resistance (61) 61 (100) 0 (0) <0.001 
 Low level resistance (22) 0 (0) 22 (100)  
qacA carriage    
 qacA positive (40) 40 (100) 0 (0) <0.001 
 qacA negative (43) 21 (49) 22  (51)  
2 p value of <0.05 was considered statistically significant.  
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 Key findings 
Screening for qacA provided previously unknown information about prevalence for this 
gene and the association of qacA with different phenotypic and genotypic characteristics. 
Namely, our findings were: 
 Prevalence for qacA carriage in New Zealand S. aureus isolates in 2014 was 
7%. Prevalence was also 7% in 2015 New Zealand MRSA isolates.  
 Carriage of qacA was not to found to have an association with hospital 
acquisition or methicillin resistance. 
 Carriage of qacA in MSSA was highly clonal and strongly associated with spa 
type t127; and fusidic acid and mupirocin resistance. 
 Carriage of qacA in MRSA was also highly clonal and also strongly associated 
with spa type t127, WR/AK1 strain. 
 Association of qacA with high level mupirocin resistance gene was supported 
by the finding that mupA gene carriage was associated with qacA carriage. This 
strongly suggests that these genes may be closely located in the S. aureus 
genome. 
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Chapter 5. Results: Phenotypic susceptibility to chlorhexidine 
 Introduction 
The qacA gene has been the interest of numerous studies due to the association of this 
gene with increased chlorhexidine tolerance and the heavy use of this antiseptic in the 
hospital environment. Studies often looked for phenotypic differences in susceptibility 
alongside genotypic screening for chlorhexidine resistance. Results from these studies 
were inconclusive, and collectively used a variety of different methods to determine 
MICs and MBCs. For this study, we used the CLSI method which was used by the 
majority of similar studies to determine whether qacA carriage in New Zealand S. aureus 
results in increased phenotypic resistance to chlorhexidine. 
 Minimum inhibitory concentration to chlorhexidine 
A total of 50 out of 53 MIC results to chlorhexidine were available for qacA positive 
strains (Figure 5). MIC results ranged from 2 – 4 mg/L. Fourteen isolates had an MIC of 
2 mg/L, and 35 isolates had an MIC of 4 mg/L.  
Forty-seven MIC results were available for the control group (qacA negative). MIC 
results also ranged from 2 – 4 mg/L with 36 isolates with an MIC of 2 mg/L, and 11 
isolates with an MIC of 4 mg/L. MIC results are summarised in Table 17 and Figure 5. 
Despite displaying similar ranges of MIC results in both groups, the MIC50 in the qacA 
positive group was higher than the MIC50 in the qacA negative group due to the frequency 
of a higher MIC among those that carried a qacA gene over the control group (Table 17). 
Although this may be a statistically significant difference (U=598.5, p=<0.001), a single 
doubling dilution factor can be the result of normal variation in this method of testing. 
The MIC distribution also does not show a natural “cut-off” value between the two 
groups due to the small range of results generated for the MIC. 
 Minimum bactericidal concentration to chlorhexidine 
MBC results were available for 50 out of 53 qacA positive strains (Figure 6). MBC results 
ranged from 2 – 32 mg/L. Twenty-nine strains had an MBC of 4 mg/L and 19 strains had 
an MBC of 8 mg/L. The lowest and highest MBC values of 2 mg/L and 32 mg/L 
respectively were both displayed by a single isolate.  
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Forty-seven out of the 53 MBC results were available for the control group. MBC results 
ranged from 2 – 8 mg/L for this group. Thirty-two isolates had an MBC of 4 mg/L, 
followed by 8 isolates with an MBC of 8 mg/L. Seven isolates had an MBC of 2 mg/L. 
MBC results are summarised in Table 18 and Figure 6. 
The MBC results are more relevant to the use of chlorhexidine as this determines the 
actual concentration to achieve a 99.9% reduction in colony forming units. Statistical 
analysis of the results does show that the qacA positive group has a higher MBC than the 
control group (U=815.5, p=0.002). 
This perceived difference in phenotypic resistance to chlorhexidine, although not 
discernible, may be due to lineage association with spa type t127 rather than to qacA 
carriage in S. aureus. 
Table 17. Summary of MIC results for qacA positive and qacA negative isolates against 
chlorhexidine 
 MIC (mg/L) 
 
Range MIC501 MIC901 
qacA positive  2 –4 4 4 
qacA negative  2 –4 2 4 





Figure 5. MIC distribution for S. aureus against chlorhexidine for qacA positive and qacA negative 
isolates 
 
Table 18. Summary of MBC results for qacA positive and qacA negative isolates against 
chlorhexidine 
 MBC (mg/L) 
 
Range MBC501 MBC901 
qacA positive  2 –32 4 8 
qacA negative  2 –8 4 8 
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 Key findings 
Our key findings for qacA carriage and concurrent phenotypic resistance in chlorhexidine 
resistance indicated the following: 
 All strains had an MIC range of 2 – 4 mg/L, with no natural cut-off value 
separating the qacA positive and control group. 
 The qacA positive group had a larger MBC range (2 – 32 mg/L) than the control 
group (2 - 8 mg/L). 
 The carriage of qacA gene does not contribute to a discernible difference in 
MIC and MBC in the spa t127 lineage. 
 Carriage of the qacA gene does not directly correlate to a higher phenotypic 
resistance using the broth microdilution method. 
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Chapter 6. Results: Genomic analysis of qacA isolates  
 Introduction 
Studies which had a typing component often found that the clonal lineage associated with 
qacA is ST239. The qacA gene has also been identified on the pSK1-family of plasmids. 
As our prevalence studies have shown in Chapter 4, qacA in New Zealand S. aureus is 
strongly associated with spa type t127 and resistance to mupirocin and fusidic acid. In 
this chapter, we set out to determine the location of the qacA gene and the links with 
other resistance genes, paying particular interest to those that confer resistance to 
mupirocin and fusidic acid. 
 Quality of sequence data and assembly from whole genome 
sequencing 
The sequence data and assembly quality was assessed using the .fastq files; and 
assembled scaffolds from SPAdes and annotation output from Nullarbor respectively. 
All isolates had passed overall quality checks in both sequence data and assembly.   
 Sequence data quality metrics 
All isolates that were sent for sequencing had a similar GC% content to S. aureus (35.2 
– 35.8%). The average phred quality score per base was a minimum of 33.5. The depth 
of read for each organism ranged from 82 to 99. Organisms were assessed as poor quality 
if the average phred quality score was less than 30 and depth was less than 50. This data 
is summarised in Table 19.  
Table 19. Quality metrics for sequence data 
 ARS1428 ARS1444 ARS1456 ARS1498 ARS14215 




33.7 33.5 33.5 33.6 33.5 
Depth 99 82 84 92 88 
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 Assembly quality metrics 
All isolates had a genome of ~2.8 Mbp which is the expected approximate genome size 
of S. aureus. N50 describes the shortest length of contig at which 50% of the genome 
mass is represented. This was used to assess the quality of assembly with a higher contig 
indicating a better quality of assembly. N50 for our group of organisms ranged from 
22,400 to 43,034 bp in length. This data is summarised in Table 20. 
Table 20. Quality metrics for assembly of sequences 
 ARS1428 ARS1444 ARS1456 ARS1498 ARS14215 
No. of contigs 148 119 139 275 255 
Total bp 2,868,177 2,798,481 2,835,458 2,819,134 2,820,959 
Max contig (bp) 116,340 159,778 86,020 74,117 109,511 




 Whole genome analysis of S. aureus strains 
The Nullarbor output provided data to assess similarities between strains. Included in this 
analysis was sequence typing results using MLST, core SNP distance analysis, and 
pairwise core SNP distance matrix between the isolates.  
 Similarity of strains 
Nullarbor analysis confirmed all the above isolates were ST1 as summarised in Table 21. 
Isolates shared an average of 94.18% similarity with results ranging from between 92.40 
to 95.85% similarity to reference genome MSSA 476. A total of 2077 core SNPs were 
found across all isolates.  
Table 21 MLST of isolates under the S. aureus scheme showing allelic profile and sequence types 
 MLST Loci Sequence Type  
(ST) arcC aroE glpF gmk pta tpi yqiL 
ARS1428 1 1 1 1 1 1 1 1 
ARS1444 1 1 1 1 1 1 1 1 
ARS1456 1 1 1 1 1 1 1 1 
ARS1498 1 1 1 1 1 1 1 1 
ARS14215 1 1 1 1 1 1 1 1 
 
All isolates that were submitted had a SNP distance which ranged from 147 SNPs to 600 
SNPs, and all isolates had a SNP distance of at least 773 from reference genome MSSA 
476. This suggests that our isolates are more closely related to one another than to the 
reference genome which is expected.  These results are summarised in Table 22. Due to 
the small number of isolates that were submitted for sequencing, there is not enough 
supporting data to suggest a cluster of similarity between any of the isolates.  
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Table 22. Pairwise Core SNP distance matrix between isolates 
ID ARS14215 ARS1428 ARS1444 ARS1456 ARS1498 Reference 
ARS14215 0 300 249 430 381 1027 
ARS1428 300 0 217 600 545 1044 
ARS1444 249 217 0 545 502 1169 
ARS1456 430 600 545 0 147 798 
ARS1498 381 545 502 147 0 773 
Reference 1027 1044 1169 798 773 0 
 
 Fusidic acid resistance gene 
Fusidic acid resistance genes were found in all strains that were sequenced. The fusC 
gene was found in all sequences except in isolate ARS14215 (2015-09180). Although 
fusC was found within these genomes, they were not found on the same contig as the 
qacA gene suggesting that these resistant determinants are not co-located. The fusC gene 
was found on the Staphylococcal cassette chromosome (SCC) which shared >99% gene 
sequence similarity within the SCC found in MSSA 476. 
The fusC gene in t127 ST1 strains were previously described by Baines et al. who 
identified this gene on SCC 476 (SCC476) of the dominant fusidic acid-resistant MSSA 
found in New Zealand (109). Fusidic acid resistance on the SCC476 mobile element is 
thus considered to be the main mode for the horizontal gene transfer of the fusC gene in 
New Zealand S. aureus isolates. The ~10.3 kb fusC element on the SCC shares >99% 
homology with the fusC element in SCCmecAK3  found in the predominant AK3 CC5 
MRSA, and the SCCmec-SCC476 element in the CC1 MRSA (Figure 7).  In addition, the 
paper has also described the co-location of the fusC with the tirS gene which encodes for 
a virulence factor which gives a selective advantage for the survival of S. aureus in the 
host (96). This, combined with use of the topical antibiotic fusidic acid may contribute 
to the predominance of the t127 strain in New Zealand. 
Despite qacA and fusC not being closely located in the genome, both fusC and qacA are 




Figure 7. Genetic organisation of the fusC gene in SCC in CC5 MRSA, CC1 MSSA and CC1 
MRSA 
Schematic showing fusC and mecA (orange and green respectively) arrangement in the SCC. White genes 
represent hypothetical proteins within the SCC. The ccr recombinase genes and the hsd genes (encode 
proteins for the restriction modification system) are also found within the SCC476 element. The grey areas 
represent regions with > 99% DNA sequence homology between the sequences. CC1 MSSA: SCC476 is 
the likely to be the location of the fusidic acid resistance gene within our t127 S. aureus genome (Figure 




 Analysis of the qacA contig  
 Co-located genes within qacA contigs 
The qacA-containing contigs were investigated for co-location with other genes of 
interest. All qacA contigs had the presence of rep indicating that the qacA gene is found 
on a plasmid. The mupA (ileS2) and blaZ genes were also found within the 
qacA-containing contigs. The presence of mupA supports the initial findings of the 
screening results found in chapter 4.4 of this thesis. Table 23 summarises the presence or 
absence of the genes of interest found on qacA contigs. 











Length of contig (bp) 27,852 27,993 30,182 27,874 27,991 
Presence of:       
 qacA + + + + + 
 qacR + + + + + 
 rep + + + + + 
 blaZ + + + + + 
 mupA (ileS2) + + + + + 
 Similarity of qacA contigs 
Percentage identity similarity was calculated in order to determine pairwise distance of 
qacA contigs between different strains. Contig 9178_51 had the lowest percentage 
similarity (92.223% – 92.346%) with others due to a ~2250 bp insertion not present in 
the other strains. Other strains had percentage similarities of greater than 99.4% with less 
than 160 nucleotide differences found among contigs 9176_107, 9177_98, 9179_223, 
and 9180_279. Mauve genome alignment viewer was used to visualise relatedness of 
qacA contigs (Figure 8). These results have been summarised in Table 24.  
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Figure 8. Mauve alignment of qacA containing contigs.  
Areas of similarities shared among the contigs are indicated by the same colour blocks with lines 
connecting areas of consensus sequences. White blocks indicate insertion sequences that were not found 
within the other contigs. 
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 The qacA plasmid 
 Plasmid structure 
 In order to determine the plasmid structure from the four qacA-containing contigs, 
consensus sequences were extracted from the CLUSTALW alignments of these contigs. 
The resulting plasmid was compared to the PacBio plasmid of a representative ST1 qacA, 
mupA, and fusC carrying t127 strain (ARS14487). PacBio of ARS14487 sequence was 
provided by the Microbiological Diagnostic Unit Public Health Laboratory, The 
University of Melbourne. The Mauve alignment of the two plasmids confirmed that the 
qacA-containing Illumina contigs have plasmids that are similar to that of the PacBio 
assembled plasmid found in ARS14487. 
 
Figure 9. Mauve alignment of pNZAK1 and PacBio assembled plasmid of ARS14487 
The two red blocks indicate areas of 100% similarity between the two plasmids. The two lines found within 
the ARS14487 block at ~22,500 bp and 27,800 bp are short sequences which are not found in pNZAK1.  
 
The PacBio assembled plasmid ARS14487 is longer than the assembled consensus 
pNZAK1 plasmid by 64 bp. The Mauve (Figure 9) and the CLUSTALW alignment 
(Figure 10) show that these extra bases are missing from the pNZAK1 plasmid at 




Figure 10. CLUSTALW alignment of pNZAK1 with PacBio assembly of ARS14487 plasmid 
The green areas within the horizontal bar represents consensus identity sequence of 100%. Breaks in the 




Figure 11. pNZAK1 containing qacA contructed from consensus sequences extracted from 
Illumina contigs 
The qacA operon (blue) is co-located with other genes of interest including the penicillinase operon (yellow 




The representative plasmid pNZAK1 (Figure 11) is ~28 kb in size. The qac operon 
consisting of qacA (blue) and corresponding regulatory gene qacR (light blue) are found 
~17 kb downstream from rep (red). Upstream from qacR is the penicillinase gene blaZ 
(orange) and the penicillin regulator protein gene blaR (yellow). Downstream from qacA 
is mupA (green) which encodes the protein for mupirocin resistance. Other genes of 
interest include cadmium resistance genes cadD, cadC; cadX (purple) and transposase 
genes (pink) adjacent to the bla operon. These transposase genes share similarities to 
transposon 552 (Tn552), a mobile genetic element known to carry the penicillinase genes 
(36). Annotations in grey are genes associated with replication and recombination 
proteins. 
 BLAST search of qacA plasmid 
A nucleotide BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) search was performed on 
the plasmid sequence. The pNZAK1 plasmid most closely resembled S. aureus plasmids 
pMW2 (AP004832) and pSAS (BX571858) sharing 73.9% similarity in identities. This 
has been visualised using the Mauve alignment viewer (Figure 12).  
The similarity between these three plasmid suggests that the pNZAK1 with the qacA 
gene belongs to the major S. aureus plasmid family of pMW2-like plasmids. This 
plasmid is ubiquitous with a wide geographical distribution from the US, UK and 
Australia (54). The pMW2-like plasmids typically carry the cadmium resistance genes 




Figure 12. Mauve alignment of pNZAK1 and the two most closely resembling plasmids from the 
BLAST search 
Areas that are in red show areas of similarity among the three different plasmids. The white block within 
pNZAK1 indicates an insertion sequence not found in the other two plasmids. 
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Plasmid pNZAK1 has an insertion sequence of ~7 kb not found in the two most closely 
resembling plasmids pSAS and pMW2 (Figure 13a). This insertion sequence contains 
qacA, qacR, and mupA (Figure 13b). A nucleotide BLAST search was performed on the 
insertion sequence. Results from this search had top hits matching to the mupA portion 
due to the larger presence of this gene on the insertion sequence with 59% query 
coverage. This was followed by hits matching to the qacA portion in various S. aureus 
sequences within NCBI database with a 39% query coverage. This may indicate that the 
incorporation of these genes on to this plasmid may be from independent recombination 
events. 
 
Figure 13. CLUSTALW alignment of pNZAK1 with pMW2 and pSAS plasmid with magnified 
insertion sequence found in pNZAK1 
a The green areas within the horizontal bar indicate consensus identity sequence of 100%. Observed 
insertion seen ~15 kb downstream from rep gene (red).  
b. Magnified view of ~7 kb insertion in spa t127 plasmid. 
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 Key findings 
Our genomic analysis sheds new light on the genetic context of genes associated with 
topical antimicrobials and biocide resistance. Key findings are: 
 The qacA gene was found on a ~28 kb plasmid and is closely co-located with 
high level mupirocin resistance gene mupA and penicillinase gene blaZ. 
 The fusC gene was found on a staphylococcal cassette chromosome.  
 Fusidic acid, mupirocin, and chlorhexidine associated resistance genes are all 
found on mobile genetic elements which are able to disseminate these genes via 
horizontal gene transfer. 
 The similarity of the plasmids in all the analysed ST1 isolates suggests clonal 
expansion of ST1. 
 The qacA-containing plasmid belongs to a major S. aureus plasmid family, 
namely the pMW2-like plasmids. 
 Both qacA and mupA are found within a ~7kb insertion sequence in the pMW2-
like backbone. 
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Chapter 7. Discussion 
 The prevalence of qacA carriage in New Zealand S. aureus is ~7% 
Prevalence of qacA was found to be ~7% for S. aureus in New Zealand. This study is the 
first to describe prevalence of qacA in New Zealand S. aureus isolates. Due to the lack 
of historical data on qacA carriage, the prevalence rates cannot be perceived as increasing 
or decreasing. By establishing the current prevalence it lays the groundwork for future 
surveillance of qacA and associated chlorhexidine resistance. This will contribute to 
future studies about the significance of qacA carriage within the S. aureus genome, with 
particular interest in circulating strains in New Zealand.  
The prevalence rates in this study are comparable to studies conducted in China and 
Korea with qacA carriage rates ranging from 4.4% to 11.8% in clinical isolates (Table 3) 
(69,74,77). The results of this study cannot be directly compared to other prevalence 
studies highlighted in Table 3 due to differences in isolate inclusion criteria. The majority 
of studies were unable to match the same parameters set out in this study, as often the 
studies (i) were targeted towards resistant phenotypes, (ii) were collected over an 
extended time-span, (iii) were collected from a single centre, or (iv) had small sample 
numbers. This is the first study to capture the prevalence of qacA in S. aureus on a 
national level with all New Zealand diagnostic laboratories taking part in the survey. This 
ensured that this was a multi-centred study which included both community and 
nosocomial isolates. The collection criteria for isolates for the 2014 survey used in this 
study enabled us to capture the true prevalence of qacA in clinical isolates at a specified 
three day window in New Zealand. This specified criteria makes this study an accurate 
snapshot representation of the current prevalence of qacA in New Zealand S. aureus.  
Similarly, the prevalence was found to be 7% among MRSA from the New Zealand 2015 
MRSA survey. Studies on qacA prevalence often focused on MRSA due to the 
importance of decolonisation particularly in wards with high colonisation pressures (44). 
The majority of these studies focused on nosocomial isolates, with one study using 
isolates from patients in a long term care facility. The MRSA survey was designed as a 
multi-centred study, incorporating both nosocomial and community isolates throughout 
New Zealand within a one month period, ensuring that this study was able to capture 
accurate prevalence rates of qacA on a national level. This makes the qacA prevalence 
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data from this study invaluable as community isolates of MRSA are a burgeoning 
reservoir of multi-resistant strains of S. aureus. This is particularly significant given the 
emergence of fusidic acid-resistant strains of MRSA, potentially driven by the heavy use 
of topical antibiotics within the community (21).  
 New Zealand S. aureus qacA carriage is highly clonal in 
community strains and is likely driven by topical antibiotic use 
As alluded to earlier, qacA was thought to be related to decreased susceptibility to 
chlorhexidine. As chlorhexidine is used extensively in healthcare facilities, we 
hypothesised that the increased exposure to chlorhexidine in this environment would lead 
to higher prevalence of qacA in hospital-acquired S. aureus. Historically, methicillin 
resistance in S. aureus was also associated with hospital-acquired isolates, thus we 
hypothesised that these two characteristics would be associated with increased 
prevalence of qacA carriage. The results of our prevalence study revealed that there was 
no association between qacA carriage and hospital acquisition. We also found that there 
was no association between methicillin resistance and qacA carriage, with similar 
prevalence rates of ~7% among MRSA in the 2015 survey and ~7% prevalence among 
New Zealand S. aureus 2014 survey.  
Although qacA was not found to be associated with the predominant AK3 MRSA, 
carriage of qacA was found in WR/AK1 MRSA. WR/AK1 is the second most common 
strain of MRSA in New Zealand and is commonly resistant to mupirocin and fusidic acid; 
and occasionally shows resistance to erythromycin (107,110). The proportion of 
WR/AK1 strains rose from 8.9% in 2014 to 11.4% in 2015, 68.2% of which are 
community-associated isolates (21,107). Concerningly, chlorhexidine and mupirocin 
decolonisation is often used to prevent HCAI, and routinely administered to newly 
admitted patients who have screened positive for MRSA carriage. This decolonisation 
strategy may become ineffective in eradicating MRSA from patients who carry this strain 
within the community. This could potentially lead to the co-selection and introduction of 
this strain into health care facilities.  
Our prevalence carriage studies also showed that qacA carriage is highly clonal and most 
commonly associated with spa type t127, belonging to ST1. Strains with spa type t127 
are the most common MSSA in New Zealand making up 15% of all MSSA collected in 
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the 2014 survey (102). Concerningly this spa type is typically associated with resistance 
to the commonly used topical anbiotics fusidic acid and mupirocin. As mentioned 
previously fusidic acid prescribing trends were associated with an increased prevalence 
of fusidic acid resistant S. aureus which were largely driven by the clones t127 and t002 
(26). Prior studies to this have also indicated that increased mupirocin use drove an 
increase in mupirocin resistance (111). Unfortunately, it is not known whether the rise in 
mupirocin-resistant strains were due to the t127, ST1 clone.  
The marked prevalence of chlorhexidine resistance associated with qacA in the 
predominant multi-resistant t127, ST1 lineage, presents a pressing challenge to 
healthcare providers to curb the expansion of this clone in the community. Strains 
belonging to the t127, ST1 lineage are likely to be resistant to the commonly used topical 
treatment options prescribed to treat, as well as decolonise, patients with S. aureus. 
Fusidic acid is currently prescribed as the preferred topical antibiotic in New Zealand for 
skin infections as this is subsidised by the Ministry of Health. In addition, eradication of 
S. aureus still uses a combination of mupirocin ointment and chlorhexidine. The co-
carriage of fusC, mupA, and qacA mediated resistance in the t127, ST1 lineage is likely 
to thrive under current antibiotic prescribing habits, which has the potential to lead to 
increased prevalence of multiply resistant strains circulating in the community. 
Additionally, the predominance of t127, ST1 clones could also lead to a greater 
likelihood of exchange of resistance genes found on mobile genetic elements. 
 Arrangement of qacA on the pNZAK1 is unique 
To date the arrangement of qacA with mupA in the plasmid of our isolates has not been 
found in its entirety by BLAST search of this sequence. Despite several studies looking 
for the co-existence of these genes in S. aureus (74,76,81–83,86,112), little is known 
about the organisation of these genes within the S. aureus genome or the organisation of 
these genes in different clonal lineages. The co-location of qacR and qacA adjacent to 
Tn552 carrying the blaZ of the pMW2-like plasmid is unsurprising as qacA is often 
found, and associated with, the penicillinase gene on other plasmids (113).  To date the 
qacA on the pMW2-like plasmid has not been previously described, and this is the first 
study to find this gene within the ubiquitous ST1 clone. 
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Numerous papers with a clonal typing component in qacA prevalence studies found that 
sequence types ST239 (CC5) was often associated with qacA carriage (76,80,81). The 
pSK1-like plasmid is the likely location of the qacA gene in the ST239 clones. The pSK1 
family of plasmids also carries genes that confers resistance to penicillin through carriage 
of Tn552, to aminoglycosides through carriage of Tn4001, and to trimethoprim through 
carriage of dfrA (114). In addition to pSK1, qacA has been associated with transmissible 
plasmids pSK105, pSK107, pSK4032, pSK4769, and pSK57 (99). Recombination events 
leading to the incorporation of qacA onto these plasmids have not been widely studied.  
The distribution of resistance and virulence genes on plasmids of S. aureus has been 
found to be lineage associated (39). McCarthy and Lindsay’s study grouped together 
plasmids based on rep gene sequences and combinations of rep genes from S. aureus 
plasmid sequences that were available in the public domain. In their study, both qacA 
and mupA were found on plasmids, however neither of these genes are core genes of any 
of the plasmid groups defined in McCarthy and Lindsay’s study (39). Plasmid groups 
were also found to be lineage-associated due to clonal expansion and restriction 
modification systems that prevent incompatible transfers of genes between lineages. 
Dissemination of the pNZAK1 plasmid in the predominant NZ strain may be attributed 
to clonal expansion from a single clone from the ST1 lineage rather than independent 
recombination events leading to the incorporation of qacA into the plasmid. This theory 
is supported by the rare finding in this study showing that qacA is associated with the 
ST1 lineage; which has not been previously described despite the frequency of qacA and 
ST1 worldwide.  
The mupA gene typically disseminates on mobile genetic elements. Insertion sequences 
flanking mupA indicate the likely transposable mechanism for the transfer of the 
mupirocin resistance gene between plasmids (115). Dissemination of mupA can also be 
through complete plasmid transfers. Transfers of these mupA carrying plasmids has been 
described among different pandemic lineages of S. aureus and in S. epidermidis (115). 
Our study found direct correlation of presence of mupA with phenotypic high level 
mupirocin resistance in New Zealand strains. Thus, mupirocin use is likely to be the 
selective factor for the maintenance of the mupA gene in pNZAK1.   
As qacA, mupA, and blaZ are co-located on the pNZAK1 plasmid, co-selection for these 
genes may be linked to the use of antimicrobials in New Zealand. A 2016 report was 
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prepared for the Ministry of Health on the prescribing trends and antibiotic consumption 
in New Zealand by ESR. The report observed an increase in consumption of the extended 
spectrum penicillin, amoxicillin, in New Zealand between 2006 and 2014 (116). This 
trend of increased amoxicillin consumption, plus the use of the topical antimicrobials 
mupirocin and fusidic acid as mentioned earlier may be a contributing factor in the 
findings of a notably high prevalence of qacA in New Zealand S. aureus isolates. 
Essentially, the use of these antibiotics has potentially led to the selection for certain 
genes and gene networks resulting in the success of the predominant lineage; in this case, 
the multi-resistant, community-associated t127, ST1 lineage.  
 Carriage of qacA in S. aureus did not show reduced susceptibility 
to chlorhexidine 
MIC and MBC findings to chlorhexidine in this study showed negligible differences 
between qacA positive and qacA negative isolates. Alternatively, qacA may not have 
been expressed under the conditions that were used for susceptibility testing. This 
outcome was similar to results found in other studies that addressed the phenotypic 
expression of the qacA gene. The methodology chosen for this study is one commonly 
used for organisms and antimicrobials for therapeutic use. Currently there is no 
standardised, reproducible method that is able to assess the effectiveness of antiseptics 
like chlorhexidine against specific organisms (90).  
Our findings are supported by Grkovic et al. who were unable to detect an increased 
expression of QacA in S. aureus in their study of the repressor protein QacR with various 
substrates (59). The chlorhexidine digluconate MIC required to inhibit binding of QacR 
to the IR1 was too high for the survival of S. aureus. The negligible differences in MIC 
and MBC found between our two groups may be within the natural tolerance levels of 
S. aureus to chlorhexidine regardless of qacA carriage status. Resistance to 
chlorhexidine, if mediated by the expression of the qacA gene, may be due to 
simultaneous exposure to other compounds or substrates. Simultaneous exposure of 
chlorhexidine and other recognised substrates may perhaps overcome the binding of 
QacR to the operator region IR1 which then increases the expression of QacA. The 
Grkovic et al. study showed substrates that increased expression of QacA included 
compounds that have also been used for antisepsis, disinfection, and preservation (42).  
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Work on qacA carriage and association with failed decolonisation strategies continues to 
be a focus area due to the reliance on chlorhexidine for the prevention of nosocomial 
infections. Batra et al. conducted a study which showed qacA/B carrying strains were still 
isolated in patients post administration of decolonisation procedures that included the use 
of chlorhexidine (117). A similar result was found in a nested case control study 
conducted in Geneva following patients post decolonisation therapy. This study showed 
that decolonisation therapy with mupirocin and chlorhexidine was less effective in 
patients who were previously colonised with qacA/B carrying ST239 S. aureus than 
patients who were colonised with non-ST239 S. aureus without qacA/B (odds ratio, 10.2 
95% confidence interval, 2.6 - 40.7 p<0.01) (112).  
Interestingly, the Batra et al study did note a threefold increase in chlorhexidine MBC in 
ST239 S. aureus when compared to non-ST239 S. aureus (117). This could mean that 
the perceived tolerance to chlorhexidine might be associated with lineage ST239, rather 
than due to the carriage of qacA/B in the ST239 S. aureus. As our phenotypic 
chlorhexidine susceptibility study matched the control group on clonal type, we were 
unable to ascertain whether the ST1 lineage shows naturally higher levels of resistance 
to chlorhexidine than other lineages found in New Zealand. Namely, qacA carriage in the 
predominant New Zealand ST1 lineage may not display increased resistance to 
chlorhexidine, instead showing resistance levels that are alike to ST1 strains without 
qacA.  
MICs and MBCs of S. aureus in phenotypic chlorhexidine resistance studies often yield 
values that are several magnitudes lower than the concentration of chlorhexidine 
solutions that are used in clinical applications (99). Thus, the argument may be made that 
increased tolerance to chlorhexidine is minimal and should not warrant concern from the 
health sector. However, an unintended consequence of widespread use of chlorhexidine 
in healthcare for decolonisation and hand antisepsis is the residual levels in the 
environment which potentially creates a selective advantage for isolates with increased 
tolerance to chlorhexidine. Additionally, studies have indicated that repeated exposure to 
sub-inhibitory levels of chlorhexidine can lead to increased MIC levels in S. aureus (99).  
Concerningly, the predominant t127, ST1 strain in New Zealand is commonly resistant 
to fusidic acid and, as demonstrated in this study, also associated with mupirocin 
resistance. Resistance to these two antibiotics along with chlorhexidine resistance make 
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a trio of topical treatment options which potentially are unable to treat the common skin 
or soft tissue infection. Failure to treat simple S. aureus infections sufficiently will 
continue to contribute to the high rates of incidence observed in New Zealand. This will 
continue to be a significant burden to New Zealand public health, and highlights the need 
to find an alternative solution to reduce the use of these topical agents in the community.  
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Thesis summary and future work 
The overarching aim of this work was to investigate the phenotypic and genotypic 
context of chlorhexidine resistance in New Zealand S. aureus isolates. This included 
establishing the prevalence rates and associations of qacA carriage with various 
characteristics including patient demographics, phenotypic susceptibility profiles and 
clonal lineages. Furthermore, this work also looked at the genetic setting of qacA with 
other resistance genes commonly associated with this strain.  
Our key findings were: 
i. That the gene associated with chlorhexidine resistance, qacA, has a prevalence of 
7% in New Zealand S. aureus isolates.  
ii. That the carriage of the qacA gene is highly clonal and is associated with the 
predominant fusidic acid- and mupirocin-resistant t127, ST1 strain, making these 
strains genotypically resistant to currently prescribed topical antibiotics and 
antiseptics. 
iii. That qacA and mupA are co-located often in fusC harbouring S. aureus strain 
suggesting the genetic potential for co-selection. 
Taken together, the association of qacA with reduced susceptibility to chlorhexidine 
alongside the high use of chlorhexidine in healthcare, may be inadvertently contributing 
to the success of the predominant t127 clone in New Zealand. This is particularly 
significant because of the high incidence rates of S. aureus infections in New Zealand 
(15). Furthermore, the t127, ST1 clone is multi-resistant, with the strain being 
synonymous with fusidic acid resistance and in 45% of cases co-resistant to mupirocin 
(100). The combination of resistance to the common topical antibiotics alongside 
chlorhexidine makes this predominant strain potentially untreatable using the first-line 
and preferred topical antibiotics and antiseptics. This makes it increasingly harder to 
execute successful decolonisation strategies to prevent nosocomial infections caused by 
S. aureus.  
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Future Work 
Based on the key findings from this study, further work is required to address the issue 
of ongoing chlorhexidine use and qacA carriage in S. aureus. Further work should focus 
on the following questions: 
How can the expression of QacA and increased phenotypic resistance to 
chlorhexidine be tested in clinical S. aureus isolates? 
This study was unable to show the association between qacA carriage in S. aureus and 
phenotypic resistance to chlorhexidine. The method described in this study is typically 
used for measuring MIC and MBC levels of organisms to antibiotics that are used for 
therapeutic purposes. Work on this aspect should develop an assay which is able to test 
the resistance to chlorhexidine under conditions which better represent the environment 
and application of chlorhexidine in a clinical setting. One factor to be considered is the 
activity of qacA-containing S. aureus when exposed to chlorhexidine on the skin of 
patients. Other compounds or substrates found within the environment that can lead to 
increased expression of QacA should also be considered when designing an assay for the 
detection of increased chlorhexidine resistance. Finding the link and establishing a 
successful method that can be used in a routine or reference laboratory can lead to better 
patient management for the eradication of S. aureus and improve clinical outcomes.  
 
What are the external factors leading to the marked prevalence of qacA in New 
Zealand S. aureus isolates? 
Due to the multi-resistance associated with qacA and the t127, ST1 clone of S. aureus in 
New Zealand, future work should aim to look at factors, other than phenotypic 
chlorhexidine resistance, that have led to the preservation of this gene in the predominant 
strain (e.g. selection by fusidic acid or mupirocin). Ongoing surveillance of qacA in New 
Zealand S. aureus strains is recommended in order to determine whether prevalence is 
on the rise or decline.  
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What genetic factors are contributing to the spread or maintenance of the qacA 
gene? 
The location of the the qacA gene in the plasmid indicates that this gene can be easily 
transferred between organisms and found alongside multiple resistance genes. Work 
should be targeted towards why and how the genes were incorporated into the pMW2-
like backbone, and the estimated introduction of the gene into New Zealand. Future 
studies should also determine the fitness cost of maintaining the gene within the 
predominant t127. 
 
What alternative is there to chlorhexidine in healthcare? 
Currently, studies are targeted towards the qacA/B carriage and the association with 
failed attempts at decolonisation strategies. Alternative options should be explored in 
future studies to find substrates, compounds, or decolonisation strategies that are able to 
be used for decolonisation of S. aureus for at-risk patients. Ideally work should focus on 
strategies that have minimal impact on gene selection so as to not lead to selection or 
development of resistance mechanisms. 
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